Nivolumab
Information
- Drug Name
- Nivolumab
- Description
- Entry(CIViC)
- 11
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Meta-Analysis of PD-L1 (CD274) Expression Status i... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Two siblings (6 and 3.5 years) from nonconsanguine... | PMS2 | PMS2 K706FS*19 PMS2 K706FS*19 | Sensitivity | true | CIViC Evidence | detail |
| Trial NCT00730639 tested monoclonal antibody nivol... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| A clinical trial of 86 patients evaluated concurre... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | false | CIViC Evidence | detail |
| A subset of patients receiving PD1/PD-L1 inhibitio... | DNMT3A | DNMT3A MUTATION DNMT3A MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this meta-analysis of 14 studies with 2857 pati... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| A meta-analysis of randomized trials to investigat... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a retrospective analysis in two separate datase... | STK11 | STK11 MUTATION STK11 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Based on a meta-analysis of 20 trials (1475 patien... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Based on a meta-analysis of 20 trials (1475 patien... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Melanoma patients treated with Anti-PD1 or anti-PD... | HLA-DRA | HLA-DRA EXPRESSION HLA-DRA EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04564157 | Active, not recruiting | Phase 3 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy | January 13, 2021 | April 1, 2031 |
| NCT01592370 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | August 2, 2012 | December 22, 2023 |
| NCT01658878 | Active, not recruiting | Phase 1/Phase 2 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | October 30, 2012 | June 28, 2024 |
| NCT01844505 | Active, not recruiting | Phase 3 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | June 11, 2013 | October 31, 2024 |
| NCT01928394 | Active, not recruiting | Phase 1/Phase 2 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | October 24, 2013 | October 31, 2024 |
| NCT01968109 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | November 5, 2013 | January 31, 2025 |
| NCT02009449 | Active, not recruiting | Phase 1 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | November 15, 2013 | August 25, 2024 |
| NCT02017717 | Active, not recruiting | Phase 3 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients | February 7, 2014 | April 8, 2024 |
| NCT02060188 | Active, not recruiting | Phase 2 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | March 12, 2014 | June 28, 2024 |
| NCT02099058 | Active, not recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | January 15, 2014 | November 16, 2024 |
| NCT02196961 | Active, not recruiting | Phase 2 | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation | June 2014 | August 31, 2024 |
| NCT02210117 | Active, not recruiting | Early Phase 1 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | November 25, 2014 | November 30, 2025 |
| NCT02224781 | Active, not recruiting | Phase 3 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | September 8, 2015 | December 31, 2024 |
| NCT02231749 | Active, not recruiting | Phase 3 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | October 16, 2014 | August 7, 2027 |
| NCT02257528 | Active, not recruiting | Phase 2 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | May 18, 2015 | March 4, 2025 |
| NCT02259621 | Active, not recruiting | Phase 2 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | September 2014 | October 2027 |
| NCT02275533 | Active, not recruiting | Phase 2 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | July 2, 2015 | August 31, 2024 |
| NCT02293980 | Active, not recruiting | Phase 1 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | November 25, 2014 | November 30, 2026 |
| NCT02314169 | Active, not recruiting | Phase 2 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | May 13, 2015 | February 15, 2025 |
| NCT02374242 | Active, not recruiting | Phase 2 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases | November 4, 2014 | December 2028 |
| NCT02379520 | Active, not recruiting | Phase 1 | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | September 2015 | October 2033 |
| NCT02388906 | Active, not recruiting | Phase 3 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma | March 19, 2015 | October 6, 2024 |
| NCT02393625 | Active, not recruiting | Phase 1 | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | May 27, 2015 | September 10, 2024 |
| NCT02393794 | Active, not recruiting | Phase 1/Phase 2 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | July 17, 2015 | July 2025 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT02428192 | Active, not recruiting | Phase 2 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | April 22, 2015 | March 5, 2025 |
| NCT02453620 | Active, not recruiting | Phase 1 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | February 12, 2016 | August 30, 2024 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT02477826 | Active, not recruiting | Phase 3 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | August 5, 2015 | August 30, 2024 |
| NCT02496208 | Active, not recruiting | Phase 1 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | July 22, 2015 | September 30, 2024 |
| NCT02498600 | Active, not recruiting | Phase 2 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | June 29, 2015 | December 31, 2024 |
| NCT02499367 | Active, not recruiting | Phase 2 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | August 2015 | August 2025 |
| NCT02530463 | Active, not recruiting | Phase 2 | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome | September 8, 2015 | September 30, 2025 |
| NCT02595944 | Active, not recruiting | Phase 3 | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | July 22, 2016 | December 31, 2025 |
| NCT02632409 | Active, not recruiting | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer | March 22, 2016 | May 27, 2027 |
| NCT02656706 | Active, not recruiting | Phase 2 | Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | July 2016 | July 2024 |
| NCT02664181 | Active, not recruiting | Phase 2 | Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial | June 6, 2017 | August 15, 2024 |
| NCT02696993 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | December 16, 2016 | December 31, 2024 |
| NCT02719613 | Active, not recruiting | Phase 2 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | July 15, 2016 | June 28, 2024 |
| NCT02743494 | Active, not recruiting | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer | July 14, 2016 | October 11, 2025 |
| NCT02754726 | Active, not recruiting | Phase 2 | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | April 2016 | December 2023 |
| NCT02758717 | Active, not recruiting | Phase 2 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | May 13, 2016 | May 13, 2024 |
| NCT02785952 | Active, not recruiting | Phase 3 | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | December 29, 2015 | April 1, 2025 |
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT02872116 | Active, not recruiting | Phase 3 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | October 12, 2016 | May 31, 2024 |
| NCT02873962 | Active, not recruiting | Phase 2 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | November 10, 2016 | July 2026 |
| NCT02879695 | Active, not recruiting | Phase 1 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | October 25, 2017 | September 6, 2024 |
| NCT02910700 | Active, not recruiting | Phase 2 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | December 9, 2016 | December 8, 2024 |
| NCT02919683 | Active, not recruiting | Phase 2 | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | November 2016 | December 2024 |
| NCT02923934 | Active, not recruiting | Phase 2 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | August 22, 2017 | December 2023 |
| NCT02927769 | Active, not recruiting | Phase 2 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment | March 28, 2017 | November 10, 2024 |
| NCT02940301 | Active, not recruiting | Phase 2 | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | December 20, 2016 | December 31, 2024 |
| NCT02966548 | Active, not recruiting | Phase 1 | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | January 4, 2017 | July 4, 2025 |
| NCT02977052 | Active, not recruiting | Phase 2 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | November 24, 2016 | June 2025 |
| NCT02978404 | Active, not recruiting | Phase 2 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | June 2, 2017 | December 31, 2023 |
| NCT02978625 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | September 27, 2017 | September 1, 2025 |
| NCT02985957 | Active, not recruiting | Phase 2 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | March 26, 2017 | January 7, 2025 |
| NCT02989636 | Active, not recruiting | Phase 1 | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | March 10, 2017 | November 2026 |
| NCT02998528 | Active, not recruiting | Phase 3 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | March 4, 2017 | November 8, 2028 |
| NCT03004833 | Active, not recruiting | Phase 2 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | February 21, 2017 | December 2023 |
| NCT03015896 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | February 14, 2017 | December 31, 2024 |
| NCT03016871 | Active, not recruiting | Phase 2 | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL | April 24, 2017 | January 30, 2026 |
| NCT03025256 | Active, not recruiting | Phase 1 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | May 2, 2018 | December 30, 2025 |
| NCT03033446 | Active, not recruiting | Phase 2 | Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma | December 20, 2016 | December 31, 2024 |
| NCT03033576 | Active, not recruiting | Phase 2 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | October 23, 2017 | December 12, 2024 |
| NCT03036098 | Active, not recruiting | Phase 3 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | March 24, 2017 | June 1, 2028 |
| NCT03038672 | Active, not recruiting | Phase 2 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | December 21, 2018 | October 25, 2024 |
| NCT03044613 | Active, not recruiting | Phase 1 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | July 11, 2017 | February 2025 |
| NCT03055013 | Active, not recruiting | Phase 3 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | April 28, 2017 | June 9, 2031 |
| NCT03057795 | Active, not recruiting | Phase 2 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | April 3, 2017 | May 30, 2024 |
| NCT03063450 | Active, not recruiting | Phase 3 | CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma | March 28, 2017 | February 2023 |
| NCT03071406 | Active, not recruiting | Phase 2 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | March 14, 2017 | July 2024 |
| NCT03092674 | Active, not recruiting | Phase 2/Phase 3 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | February 2, 2018 | October 29, 2024 |
| NCT03107182 | Active, not recruiting | Phase 2 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer | June 27, 2017 | July 2025 |
| NCT03110978 | Active, not recruiting | Phase 2 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | June 26, 2017 | June 30, 2026 |
| NCT03122522 | Active, not recruiting | Phase 2 | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | April 17, 2017 | April 2025 |
| NCT03134118 | Active, not recruiting | Phase 2 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | April 11, 2018 | July 2024 |
| NCT03141177 | Active, not recruiting | Phase 3 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | August 22, 2017 | April 17, 2024 |
| NCT03143153 | Active, not recruiting | Phase 3 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | June 29, 2017 | January 13, 2025 |
| NCT03143270 | Active, not recruiting | Early Phase 1 | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer | April 28, 2017 | April 2025 |
| NCT03146650 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | May 19, 2017 | August 11, 2025 |
| NCT03158129 | Active, not recruiting | Phase 2 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | June 9, 2017 | December 31, 2024 |
| NCT03171025 | Active, not recruiting | Phase 2 | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer | July 10, 2017 | October 31, 2027 |
| NCT03172624 | Active, not recruiting | Phase 2 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | May 26, 2017 | May 2025 |
| NCT03172754 | Active, not recruiting | Phase 1/Phase 2 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | June 12, 2017 | April 6, 2025 |
| NCT03203473 | Active, not recruiting | Phase 2 | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | October 26, 2017 | November 30, 2024 |
| NCT03215706 | Active, not recruiting | Phase 3 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | August 24, 2017 | January 19, 2026 |
| NCT03223155 | Active, not recruiting | Phase 1 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer | September 7, 2017 | December 2027 |
| NCT03233347 | Active, not recruiting | Phase 2 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | October 13, 2017 | July 8, 2025 |
| NCT03233711 | Active, not recruiting | Phase 3 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | July 5, 2018 | December 31, 2025 |
| NCT03241186 | Active, not recruiting | Phase 2 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | September 12, 2017 | September 2023 |
| NCT03245892 | Active, not recruiting | Phase 1 | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | August 4, 2017 | August 2025 |
| NCT03246958 | Active, not recruiting | Phase 2 | Nivolumab Plus Ipilimumab in Thyroid Cancer | October 3, 2017 | March 31, 2025 |
| NCT03247712 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | January 15, 2018 | December 2026 |
| NCT03267498 | Active, not recruiting | Phase 2 | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | February 14, 2018 | April 30, 2024 |
| NCT03274258 | Active, not recruiting | Phase 2 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | December 13, 2017 | July 31, 2025 |
| NCT03282344 | Active, not recruiting | Phase 2 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | September 12, 2017 | September 2025 |
| NCT03285321 | Active, not recruiting | Phase 2 | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | September 15, 2017 | December 2024 |
| NCT03292263 | Active, not recruiting | Phase 1/Phase 2 | ASCT With Nivolumab in Patients With Multiple Myeloma | April 24, 2017 | December 30, 2024 |
| NCT03297593 | Active, not recruiting | Phase 2 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | December 13, 2017 | September 2026 |
| NCT03307616 | Active, not recruiting | Phase 2 | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | October 4, 2017 | October 31, 2025 |
| NCT03333616 | Active, not recruiting | Phase 2 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | December 28, 2017 | May 31, 2025 |
| NCT03337919 | Active, not recruiting | Phase 2 | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma | December 3, 2018 | February 28, 2026 |
| NCT03338790 | Active, not recruiting | Phase 2 | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | December 19, 2017 | September 15, 2024 |
| NCT03341936 | Active, not recruiting | Phase 2 | Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN | March 15, 2018 | July 6, 2026 |
| NCT03347838 | Active, not recruiting | Phase 2 | Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers | January 30, 2019 | December 2026 |
| NCT03355560 | Active, not recruiting | Phase 2 | Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy | December 6, 2017 | July 2024 |
| NCT03355976 | Active, not recruiting | Phase 2 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | April 30, 2018 | December 2025 |
| NCT03366272 | Active, not recruiting | Phase 2/Phase 3 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients | December 5, 2017 | November 2024 |
| NCT03367741 | Active, not recruiting | Phase 2 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | April 16, 2018 | December 31, 2024 |
| NCT03369223 | Active, not recruiting | Phase 1/Phase 2 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | December 6, 2017 | September 19, 2024 |
| NCT03370276 | Active, not recruiting | Phase 1/Phase 2 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | December 20, 2017 | August 2024 |
| NCT03377023 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | February 2, 2018 | November 2025 |
| NCT03377361 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | February 1, 2018 | March 11, 2024 |
| NCT03382561 | Active, not recruiting | Phase 2 | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | May 2, 2018 | December 31, 2024 |
| NCT03383302 | Active, not recruiting | Phase 1/Phase 2 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects | February 8, 2018 | February 2026 |
| NCT03383458 | Active, not recruiting | Phase 3 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | April 18, 2018 | December 16, 2025 |
| NCT03388190 | Active, not recruiting | Phase 2 | METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin | May 29, 2018 | June 30, 2025 |
| NCT03400332 | Active, not recruiting | Phase 1/Phase 2 | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | February 12, 2018 | November 30, 2025 |
| NCT03405155 | Active, not recruiting | Phase 2 | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | January 17, 2018 | December 31, 2025 |
| NCT03414684 | Active, not recruiting | Phase 2 | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | January 30, 2018 | June 30, 2025 |
| NCT03439891 | Active, not recruiting | Phase 2 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | April 16, 2018 | November 30, 2024 |
| NCT03442569 | Active, not recruiting | Phase 2 | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | March 9, 2018 | December 22, 2024 |
| NCT03446040 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | March 8, 2018 | April 15, 2025 |
| NCT03447470 | Active, not recruiting | Phase 1 | Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | March 18, 2019 | September 29, 2023 |
| NCT03449108 | Active, not recruiting | Phase 2 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | April 27, 2018 | June 30, 2025 |
| NCT03452579 | Active, not recruiting | Phase 2 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | May 21, 2018 | December 30, 2022 |
| NCT03459222 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | May 30, 2018 | November 10, 2026 |
| NCT03463408 | Active, not recruiting | Early Phase 1 | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | July 17, 2018 | August 1, 2025 |
| NCT03469960 | Active, not recruiting | Phase 3 | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | May 2, 2018 | December 2024 |
| NCT03470922 | Active, not recruiting | Phase 2/Phase 3 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | April 11, 2018 | December 16, 2025 |
| NCT03472586 | Active, not recruiting | Phase 2 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | May 2, 2018 | December 31, 2024 |
| NCT03475134 | Active, not recruiting | Phase 1 | TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) | February 21, 2018 | June 30, 2026 |
| NCT03484819 | Active, not recruiting | Phase 2 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | December 13, 2019 | September 22, 2024 |
| NCT03487666 | Active, not recruiting | Phase 2 | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | May 21, 2018 | December 2022 |
| NCT03496662 | Active, not recruiting | Phase 1/Phase 2 | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | August 31, 2018 | October 14, 2024 |
| NCT03502330 | Active, not recruiting | Phase 1 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | June 9, 2018 | October 2027 |
| NCT03502733 | Active, not recruiting | Phase 1 | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | August 14, 2018 | July 1, 2024 |
| NCT03508570 | Active, not recruiting | Phase 1 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | September 21, 2018 | April 30, 2025 |
| NCT03521570 | Active, not recruiting | Phase 2 | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | June 28, 2018 | December 7, 2024 |
| NCT03522246 | Active, not recruiting | Phase 3 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | May 14, 2018 | December 30, 2030 |
| NCT03528408 | Active, not recruiting | Phase 2 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | July 26, 2018 | June 2023 |
| NCT03543189 | Active, not recruiting | Phase 1/Phase 2 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | October 3, 2018 | December 2024 |
| NCT03544736 | Active, not recruiting | Phase 1/Phase 2 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | April 26, 2018 | December 31, 2040 |
| NCT03547999 | Active, not recruiting | Phase 2 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | June 26, 2018 | December 31, 2024 |
| NCT03552380 | Active, not recruiting | Phase 2 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | August 31, 2018 | August 2023 |
| NCT03563248 | Active, not recruiting | Phase 2 | Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | August 10, 2018 | June 2027 |
| NCT03570619 | Active, not recruiting | Phase 2 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | December 14, 2018 | December 2024 |
| NCT03575793 | Active, not recruiting | Phase 1/Phase 2 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | September 6, 2018 | July 1, 2024 |
| NCT03576612 | Active, not recruiting | Phase 1 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | February 27, 2018 | October 31, 2023 |
| NCT03583086 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | July 10, 2018 | July 2025 |
| NCT03585465 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | March 26, 2019 | January 2028 |
| NCT03586999 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | November 7, 2018 | December 2024 |
| NCT03591731 | Active, not recruiting | Phase 2 | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | January 2, 2019 | September 2024 |
| NCT03595124 | Active, not recruiting | Phase 2 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | January 8, 2019 | September 30, 2027 |
| NCT03600155 | Active, not recruiting | Phase 1 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | October 11, 2018 | March 31, 2026 |
| NCT03600350 | Active, not recruiting | Phase 2 | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | September 10, 2018 | November 2024 |
| NCT03610711 | Active, not recruiting | Phase 1/Phase 2 | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | March 6, 2019 | April 2025 |
| NCT03628209 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma | October 3, 2019 | December 2024 |
| NCT03631641 | Active, not recruiting | Phase 2 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | August 21, 2018 | December 31, 2020 |
| NCT03635892 | Active, not recruiting | Phase 2 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | August 13, 2018 | August 2024 |
| NCT03637543 | Active, not recruiting | Phase 2 | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | October 18, 2018 | March 31, 2025 |
| NCT03639935 | Active, not recruiting | Phase 2 | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | March 28, 2019 | February 2025 |
| NCT03642067 | Active, not recruiting | Phase 2 | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | February 12, 2019 | February 23, 2025 |
| NCT03646123 | Active, not recruiting | Phase 2 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | January 28, 2019 | June 7, 2026 |
| NCT03646461 | Active, not recruiting | Phase 2 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC | October 17, 2018 | May 30, 2025 |
| NCT03647969 | Active, not recruiting | Phase 2 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | November 7, 2018 | March 2024 |
| NCT03650894 | Active, not recruiting | Phase 2 | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | April 3, 2019 | April 2025 |
| NCT03655002 | Active, not recruiting | Phase 1 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | February 21, 2019 | December 15, 2024 |
| NCT03656718 | Active, not recruiting | Phase 1/Phase 2 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | October 31, 2018 | March 7, 2025 |
| NCT03661320 | Active, not recruiting | Phase 3 | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer | November 6, 2018 | December 30, 2027 |
| NCT03689699 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | October 11, 2018 | January 2025 |
| NCT03692325 | Active, not recruiting | Phase 2 | Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia | December 5, 2018 | August 30, 2024 |
| NCT03711058 | Active, not recruiting | Phase 1/Phase 2 | Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | January 17, 2019 | June 30, 2025 |
| NCT03712202 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | November 28, 2018 | September 23, 2024 |
| NCT03719131 | Active, not recruiting | Phase 2 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | June 5, 2019 | September 13, 2024 |
| NCT03728361 | Active, not recruiting | Phase 2 | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | December 31, 2018 | December 31, 2024 |
| NCT03739619 | Active, not recruiting | Phase 1/Phase 2 | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | November 26, 2018 | December 22, 2024 |
| NCT03743662 | Active, not recruiting | Phase 2 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | November 12, 2018 | November 2024 |
| NCT03743766 | Active, not recruiting | Phase 2 | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | March 29, 2019 | July 31, 2027 |
| NCT03749018 | Active, not recruiting | Phase 2 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | January 2, 2019 | July 31, 2024 |
| NCT03769155 | Active, not recruiting | Phase 1 | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma | December 13, 2018 | December 15, 2032 |
| NCT03770416 | Active, not recruiting | Phase 2 | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | February 15, 2019 | June 30, 2025 |
| NCT03776487 | Active, not recruiting | Phase 2 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | January 7, 2019 | December 30, 2026 |
| NCT03785873 | Active, not recruiting | Phase 1/Phase 2 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | May 22, 2019 | May 2025 |
| NCT03789110 | Active, not recruiting | Phase 2 | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | March 8, 2019 | June 19, 2024 |
| NCT03793166 | Active, not recruiting | Phase 3 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | June 7, 2019 | September 15, 2024 |
| NCT03800602 | Active, not recruiting | Phase 2 | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | January 15, 2019 | January 31, 2025 |
| NCT03807765 | Active, not recruiting | Phase 1 | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases | January 30, 2019 | June 14, 2024 |
| NCT03816332 | Active, not recruiting | Phase 1 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | November 8, 2019 | September 22, 2024 |
| NCT03816358 | Active, not recruiting | Phase 1 | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | December 9, 2019 | January 31, 2025 |
| NCT03818685 | Active, not recruiting | Phase 2 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | July 2, 2019 | May 1, 2024 |
| NCT03825367 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | November 29, 2019 | March 30, 2024 |
| NCT03829111 | Active, not recruiting | Phase 1 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | May 14, 2019 | June 11, 2024 |
| NCT03829722 | Active, not recruiting | Phase 2 | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | September 5, 2019 | September 2024 |
| NCT03838159 | Active, not recruiting | Phase 2 | NADIM II: Neo-Adjuvant Immunotherapy | May 15, 2019 | November 30, 2028 |
| NCT03838263 | Active, not recruiting | Phase 2 | Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer | July 25, 2019 | November 2024 |
| NCT03843294 | Active, not recruiting | Phase 1 | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | June 24, 2019 | May 2025 |
| NCT03850067 | Active, not recruiting | Phase 1 | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | March 12, 2019 | June 26, 2024 |
| NCT03854032 | Active, not recruiting | Phase 2 | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | April 9, 2019 | December 2025 |
| NCT03865082 | Active, not recruiting | Phase 2 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | October 29, 2019 | April 2022 |
| NCT03867799 | Active, not recruiting | Phase 2 | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | March 27, 2019 | September 2024 |
| NCT03873402 | Active, not recruiting | Phase 3 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | June 21, 2019 | March 11, 2025 |
| NCT03884998 | Active, not recruiting | Phase 1 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | February 26, 2019 | July 16, 2024 |
| NCT03890952 | Active, not recruiting | Phase 2 | Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma | October 1, 2018 | August 1, 2023 |
| NCT03906071 | Active, not recruiting | Phase 3 | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | July 15, 2019 | April 30, 2024 |
| NCT03907488 | Active, not recruiting | Phase 3 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | August 29, 2019 | April 1, 2025 |
| NCT03907852 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | April 15, 2019 | November 2, 2028 |
| NCT03914300 | Active, not recruiting | Phase 2 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | February 10, 2020 | October 31, 2024 |
| NCT03914443 | Active, not recruiting | Phase 1 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | May 7, 2019 | March 1, 2024 |
| NCT03929029 | Active, not recruiting | Phase 1 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | November 11, 2020 | September 30, 2028 |
| NCT03937219 | Active, not recruiting | Phase 3 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | June 25, 2019 | March 2025 |
| NCT03970252 | Active, not recruiting | Early Phase 1 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | July 24, 2019 | April 2026 |
| NCT03980925 | Active, not recruiting | Phase 2 | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | October 11, 2019 | December 2023 |
| NCT03981146 | Active, not recruiting | Phase 2 | A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | August 28, 2019 | July 1, 2024 |
| NCT03994601 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | September 6, 2019 | May 14, 2025 |
| NCT03995017 | Active, not recruiting | Phase 1/Phase 2 | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma | January 9, 2020 | December 2024 |
| NCT03999749 | Active, not recruiting | Phase 2 | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | June 11, 2019 | November 1, 2024 |
| NCT04013542 | Active, not recruiting | Phase 1 | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | September 13, 2019 | December 31, 2024 |
| NCT04021043 | Active, not recruiting | Phase 1/Phase 2 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | August 19, 2019 | August 29, 2024 |
| NCT04022980 | Active, not recruiting | Phase 1 | Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma | March 31, 2020 | December 2024 |
| NCT04024878 | Active, not recruiting | Phase 1 | NeoVax With Nivolumab in Patients With Ovarian Cancer | November 20, 2020 | April 30, 2029 |
| NCT04025879 | Active, not recruiting | Phase 3 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | November 5, 2019 | September 30, 2024 |
| NCT04026412 | Active, not recruiting | Phase 3 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery | October 8, 2019 | December 3, 2026 |
| NCT04039607 | Active, not recruiting | Phase 3 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | September 30, 2019 | September 30, 2026 |
| NCT04040231 | Active, not recruiting | Phase 1 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | July 24, 2019 | July 2024 |
| NCT04042753 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | July 31, 2019 | July 2024 |
| NCT04043195 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | August 14, 2019 | December 2025 |
| NCT04047706 | Active, not recruiting | Phase 1 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | August 13, 2019 | June 1, 2025 |
| NCT04050761 | Active, not recruiting | A Study of Nivolumab in Patients With Head and Neck Cancer. | June 26, 2019 | September 8, 2024 | |
| NCT04062656 | Active, not recruiting | Phase 2 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG | September 26, 2019 | June 1, 2025 |
| NCT04078295 | Active, not recruiting | Phase 1/Phase 2 | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | September 5, 2019 | January 31, 2024 |
| NCT04079712 | Active, not recruiting | Phase 2 | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | August 6, 2020 | October 1, 2024 |
| NCT04085250 | Active, not recruiting | Phase 2 | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy | November 28, 2019 | January 31, 2025 |
| NCT04099251 | Active, not recruiting | Phase 3 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma | October 28, 2019 | June 29, 2027 |
| NCT04100018 | Active, not recruiting | Phase 3 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | February 6, 2020 | June 27, 2024 |
| NCT04106414 | Active, not recruiting | Phase 2 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | September 24, 2019 | September 2024 |
| NCT04126070 | Active, not recruiting | Phase 2 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | May 11, 2020 | June 30, 2025 |
| NCT04133948 | Active, not recruiting | Phase 1/Phase 2 | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma | January 7, 2020 | November 2024 |
| NCT04146324 | Active, not recruiting | An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia | December 12, 2019 | December 9, 2026 | |
| NCT04162015 | Active, not recruiting | Phase 1 | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | November 12, 2019 | November 2025 |
| NCT04170556 | Active, not recruiting | Phase 1/Phase 2 | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | March 16, 2020 | August 2024 |
| NCT04172402 | Active, not recruiting | Phase 2 | NGS as the First-line Treatment in Advanced Biliary Tract Cancer | December 27, 2019 | December 31, 2024 |
| NCT04187404 | Active, not recruiting | Phase 1/Phase 2 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | July 23, 2020 | November 30, 2025 |
| NCT04195139 | Active, not recruiting | Phase 2 | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM | February 22, 2018 | December 31, 2025 |
| NCT04205409 | Active, not recruiting | Phase 2 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | June 5, 2020 | August 1, 2029 |
| NCT04239040 | Active, not recruiting | Phase 1 | GVAX Plus Checkpoint Blockade in Neuroblastoma | January 29, 2020 | January 1, 2027 |
| NCT04247165 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. | June 2, 2020 | December 2024 |
| NCT04270864 | Active, not recruiting | Phase 1 | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers | April 10, 2020 | February 2026 |
| NCT04277442 | Active, not recruiting | Phase 1 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | March 11, 2020 | June 4, 2025 |
| NCT04278144 | Active, not recruiting | Phase 1/Phase 2 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | February 24, 2020 | October 31, 2026 |
| NCT04300244 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | May 4, 2020 | March 15, 2027 |
| NCT04309409 | Active, not recruiting | Phase 3 | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | July 1, 2020 | January 2028 |
| NCT04310007 | Active, not recruiting | Phase 2 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | July 13, 2020 | September 30, 2024 |
| NCT04317105 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | July 17, 2020 | December 31, 2024 |
| NCT04331067 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | November 19, 2020 | May 31, 2026 |
| NCT04339738 | Active, not recruiting | Phase 2 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | November 4, 2020 | September 30, 2024 |
| NCT04349267 | Active, not recruiting | Phase 1/Phase 2 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | July 14, 2020 | May 30, 2025 |
| NCT04361162 | Active, not recruiting | Phase 2 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | May 18, 2020 | October 2026 |
| NCT04362839 | Active, not recruiting | Phase 1 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | May 27, 2020 | June 30, 2024 |
| NCT04396860 | Active, not recruiting | Phase 2/Phase 3 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | September 1, 2020 | March 11, 2025 |
| NCT04401774 | Active, not recruiting | Phase 2 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | May 22, 2020 | May 22, 2026 |
| NCT04401995 | Active, not recruiting | Phase 2 | Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab | September 2, 2020 | July 30, 2028 |
| NCT04420975 | Active, not recruiting | Phase 1 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | October 29, 2020 | January 31, 2026 |
| NCT04431635 | Active, not recruiting | Phase 1 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | June 15, 2020 | June 2026 |
| NCT04457284 | Active, not recruiting | Phase 2 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | November 18, 2020 | July 2025 |
| NCT04463368 | Active, not recruiting | Phase 1 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases | March 8, 2021 | December 1, 2024 |
| NCT04477512 | Active, not recruiting | Phase 1 | Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) | February 19, 2021 | March 31, 2026 |
| NCT04493203 | Active, not recruiting | Phase 2 | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | December 18, 2020 | February 28, 2029 |
| NCT04514484 | Active, not recruiting | Phase 1 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | November 22, 2021 | November 2, 2025 |
| NCT04526730 | Active, not recruiting | Phase 2 | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | December 22, 2020 | June 15, 2028 |
| NCT04551430 | Active, not recruiting | Phase 2 | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | January 5, 2021 | June 1, 2030 |
| NCT04552223 | Active, not recruiting | Phase 2 | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | November 10, 2020 | December 2026 |
| NCT04567615 | Active, not recruiting | Phase 2 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | February 4, 2021 | September 25, 2024 |
| NCT04575922 | Active, not recruiting | Phase 2 | Nivolumab+Ipilimumab+RT in MSS mCRC | October 5, 2020 | June 2024 |
| NCT04581382 | Active, not recruiting | Early Phase 1 | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | December 14, 2020 | October 31, 2024 |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT04606316 | Active, not recruiting | Phase 1 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | February 1, 2021 | December 31, 2024 |
| NCT04610671 | Active, not recruiting | Phase 1 | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | October 26, 2020 | March 2025 |
| NCT04623775 | Active, not recruiting | Phase 2 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | February 17, 2021 | September 16, 2025 |
| NCT04624178 | Active, not recruiting | Phase 2 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | November 5, 2020 | November 5, 2024 |
| NCT04637594 | Active, not recruiting | Phase 3 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | December 10, 2020 | September 2030 |
| NCT04695977 | Active, not recruiting | Phase 2/Phase 3 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | February 24, 2021 | July 19, 2024 |
| NCT04717154 | Active, not recruiting | Phase 2 | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | January 19, 2021 | February 15, 2026 |
| NCT04729322 | Active, not recruiting | Phase 2 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | February 22, 2021 | December 31, 2024 |
| NCT04735978 | Active, not recruiting | Phase 1 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | December 29, 2020 | April 2024 |
| NCT04757363 | Active, not recruiting | Phase 2 | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | February 11, 2021 | February 2025 |
| NCT04778904 | Active, not recruiting | Phase 1/Phase 2 | First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV | December 22, 2020 | February 21, 2023 |
| NCT04781855 | Active, not recruiting | Phase 1 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | July 14, 2022 | December 31, 2024 |
| NCT04785287 | Active, not recruiting | Phase 1/Phase 2 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | March 29, 2021 | May 27, 2025 |
| NCT04785820 | Active, not recruiting | Phase 2 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | June 25, 2021 | June 30, 2025 |
| NCT04803877 | Active, not recruiting | Phase 2 | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | June 4, 2021 | June 2026 |
| NCT04831320 | Active, not recruiting | Phase 2 | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | September 28, 2021 | September 30, 2025 |
| NCT04835805 | Active, not recruiting | Phase 1 | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | May 13, 2021 | November 28, 2025 |
| NCT04845139 | Active, not recruiting | N/A | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | July 2, 2022 | November 30, 2022 |
| NCT04863885 | Active, not recruiting | Phase 1/Phase 2 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | April 30, 2021 | October 2025 |
| NCT04871594 | Active, not recruiting | Phase 1 | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer | August 23, 2021 | June 2, 2026 |
| NCT04879368 | Active, not recruiting | Phase 3 | RegoNivo vs Standard of Care Chemotherapy in AGOC | June 1, 2021 | June 1, 2026 |
| NCT04887870 | Active, not recruiting | Phase 2/Phase 3 | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | June 30, 2021 | April 19, 2025 |
| NCT04891770 | Active, not recruiting | Phase 2 | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | August 14, 2021 | July 2024 |
| NCT04904302 | Active, not recruiting | Phase 2 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | May 3, 2022 | January 31, 2025 |
| NCT04935229 | Active, not recruiting | Phase 1 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | August 2, 2021 | January 2025 |
| NCT04938232 | Active, not recruiting | Phase 2 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | June 4, 2021 | August 1, 2026 |
| NCT04940299 | Active, not recruiting | Phase 2 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | September 23, 2021 | December 31, 2024 |
| NCT04943900 | Active, not recruiting | Phase 1 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | August 9, 2021 | June 4, 2028 |
| NCT04963283 | Active, not recruiting | Phase 2 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | June 23, 2021 | February 9, 2026 |
| NCT04967196 | Active, not recruiting | Phase 1 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | September 16, 2021 | July 2025 |
| NCT04969887 | Active, not recruiting | Phase 2 | Combination Immunotherapy in Rare Cancers Under InvesTigation | August 3, 2021 | March 2028 |
| NCT04987203 | Active, not recruiting | Phase 3 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | September 9, 2021 | August 1, 2025 |
| NCT05002569 | Active, not recruiting | Phase 3 | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | October 19, 2021 | November 1, 2029 |
| NCT05122546 | Active, not recruiting | Phase 1 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | November 1, 2021 | October 25, 2024 |
| NCT05150236 | Active, not recruiting | Phase 2 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | April 29, 2022 | December 2024 |
| NCT05169957 | Active, not recruiting | Phase 1 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | August 9, 2022 | June 13, 2025 |
| NCT05178043 | Active, not recruiting | Phase 2 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | August 1, 2021 | December 1, 2025 |
| NCT05200143 | Active, not recruiting | Phase 2 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | June 8, 2022 | June 2031 |
| NCT05220722 | Active, not recruiting | Phase 1/Phase 2 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | March 2, 2022 | January 2025 |
| NCT05298592 | Active, not recruiting | Phase 1 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | March 31, 2022 | July 15, 2024 |
| NCT05302921 | Active, not recruiting | Phase 2 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | February 18, 2022 | July 1, 2025 |
| NCT05352828 | Active, not recruiting | Phase 1 | Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | July 25, 2022 | December 15, 2037 |
| NCT05354102 | Active, not recruiting | Phase 1 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | May 1, 2022 | November 2025 |
| NCT05394740 | Active, not recruiting | Phase 1/Phase 2 | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | June 6, 2022 | November 2025 |
| NCT05407675 | Active, not recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | August 2, 2022 | October 14, 2025 |
| NCT05543629 | Active, not recruiting | Phase 1/Phase 2 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | October 4, 2022 | November 1, 2026 |
| NCT05568095 | Active, not recruiting | Phase 3 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | November 21, 2022 | May 2026 |
| NCT05663710 | Active, not recruiting | Phase 1/Phase 2 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | June 30, 2023 | October 30, 2027 |
| NCT05696548 | Active, not recruiting | Phase 2 | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | July 2, 2019 | July 2025 |
| NCT05704933 | Active, not recruiting | Early Phase 1 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | June 6, 2023 | January 2027 |
| NCT06452329 | Active, not recruiting | A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer | February 28, 2024 | July 31, 2025 | |
| NCT03126643 | Approved for marketing | Expanded Access to Nivolumab (Opdivo) | |||
| NCT06361576 | Completed | Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada | September 5, 2023 | January 25, 2024 | |
| NCT03792750 | Completed | Phase 1/Phase 2 | A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors | December 31, 2018 | December 18, 2020 |
| NCT03925246 | Completed | Phase 2 | Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas | July 30, 2019 | August 18, 2021 |
| NCT03798314 | Completed | Phase 1 | Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma | January 30, 2019 | September 15, 2021 |
| NCT03798639 | Completed | Phase 1 | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | January 7, 2019 | December 2, 2022 |
| NCT03922880 | Completed | Phase 1 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | April 16, 2019 | January 20, 2023 |
| NCT03894891 | Completed | Phase 2 | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | June 11, 2019 | December 16, 2022 |
| NCT03892044 | Completed | Phase 1 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | November 5, 2019 | February 14, 2024 |
| NCT03841201 | Completed | Phase 2 | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | June 12, 2019 | May 2, 2023 |
| NCT03841110 | Completed | Phase 1 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | February 15, 2019 | November 15, 2022 |
| NCT03834623 | Completed | Phase 2 | Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | May 14, 2019 | August 4, 2021 |
| NCT03832621 | Completed | Phase 2 | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | March 25, 2019 | September 30, 2021 |
| NCT03817125 | Completed | Phase 1 | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | January 28, 2019 | March 4, 2022 |
| NCT04761198 | Completed | Phase 1/Phase 2 | A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors. | March 23, 2021 | September 30, 2023 |
| NCT03044626 | Completed | Phase 2 | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC | February 10, 2017 | December 31, 2020 |
| NCT03043599 | Completed | Phase 1/Phase 2 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | February 13, 2017 | November 14, 2023 |
| NCT04749602 | Completed | Phase 2 | Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. | August 10, 2020 | March 1, 2023 |
| NCT03021993 | Completed | Phase 2 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | May 30, 2017 | November 15, 2021 |
| NCT03015740 | Completed | Phase 1/Phase 2 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | April 23, 2017 | September 6, 2022 |
| NCT03158272 | Completed | Phase 1 | A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread | May 25, 2017 | October 23, 2019 |
| NCT03161379 | Completed | Phase 2 | GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | February 2, 2018 | February 28, 2024 |
| NCT03013335 | Completed | Phase 2 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen | January 2016 | June 30, 2021 |
| NCT03162731 | Completed | Early Phase 1 | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer | May 11, 2017 | November 16, 2022 |
| NCT03165409 | Completed | Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread | February 27, 2017 | September 30, 2017 | |
| NCT03012581 | Completed | Phase 2 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | June 16, 2017 | November 11, 2023 |
| NCT03006705 | Completed | Phase 3 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | January 31, 2017 | March 31, 2023 |
| NCT03003637 | Completed | Phase 1/Phase 2 | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | February 28, 2017 | February 12, 2021 |
| NCT03001882 | Completed | Phase 2 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | March 29, 2017 | April 24, 2023 |
| NCT02999295 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer | January 2017 | August 2019 |
| NCT02996110 | Completed | Phase 2 | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma | February 2, 2017 | November 23, 2021 |
| NCT06163170 | Completed | A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | August 14, 2023 | November 10, 2023 | |
| NCT02989714 | Completed | Phase 1/Phase 2 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | March 16, 2017 | June 23, 2020 |
| NCT03123783 | Completed | Phase 1/Phase 2 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | July 10, 2017 | November 16, 2020 |
| NCT02983006 | Completed | Phase 1 | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | October 2016 | January 1, 2021 |
| NCT02982954 | Completed | Phase 4 | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | January 16, 2017 | October 6, 2021 |
| NCT03184870 | Completed | Phase 1/Phase 2 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | August 8, 2017 | June 14, 2023 |
| NCT03190174 | Completed | Phase 1/Phase 2 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | August 24, 2017 | December 2, 2021 |
| NCT03190265 | Completed | Phase 2 | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | December 14, 2017 | August 23, 2023 |
| NCT03192943 | Completed | Phase 1 | A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors | June 23, 2017 | December 11, 2018 |
| NCT03195478 | Completed | Phase 1/Phase 2 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | August 2, 2017 | January 5, 2024 |
| NCT03195491 | Completed | Phase 3 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia | December 25, 2017 | June 8, 2021 |
| NCT04698187 | Completed | Phase 2 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | March 11, 2021 | February 5, 2024 |
| NCT02973113 | Completed | Phase 1 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | February 16, 2016 | July 11, 2020 |
| NCT03203876 | Completed | Phase 1 | A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | July 14, 2017 | August 6, 2020 |
| NCT03214250 | Completed | Phase 1/Phase 2 | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | July 21, 2017 | February 25, 2022 |
| NCT02970981 | Completed | Phase 2 | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | November 29, 2016 | May 2, 2022 |
| NCT03215810 | Completed | Phase 1 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | October 11, 2017 | June 9, 2023 |
| NCT02960906 | Completed | Phase 2 | A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer | May 31, 2017 | February 15, 2021 |
| NCT02960854 | Completed | Phase 1 | A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock. | December 7, 2016 | January 5, 2018 |
| NCT03222076 | Completed | Phase 2 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | September 28, 2017 | September 14, 2022 |
| NCT02960230 | Completed | Phase 1/Phase 2 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | November 18, 2016 | December 31, 2023 |
| NCT03224871 | Completed | Early Phase 1 | UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | August 11, 2017 | January 10, 2020 |
| NCT02955251 | Completed | Phase 1 | A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | November 18, 2016 | October 29, 2019 |
| NCT03229278 | Completed | Phase 1 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | October 3, 2017 | October 30, 2022 |
| NCT02947386 | Completed | Phase 1 | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | June 29, 2017 | September 8, 2022 |
| NCT02946671 | Completed | Phase 1 | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients | March 2016 | March 2020 |
| NCT03238365 | Completed | Early Phase 1 | Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck | August 10, 2017 | September 8, 2022 |
| NCT03241173 | Completed | Phase 1/Phase 2 | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | October 9, 2017 | September 17, 2019 |
| NCT03126110 | Completed | Phase 1/Phase 2 | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | April 25, 2017 | November 9, 2021 |
| NCT03241745 | Completed | Phase 2 | A Study of Nivolumab in Selected Uterine Cancer Patients | August 3, 2017 | April 1, 2024 |
| NCT02944396 | Completed | Phase 1 | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | December 23, 2016 | October 2, 2019 |
| NCT04887194 | Completed | Phase 1 | PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | April 8, 2021 | December 22, 2022 |
| NCT02941744 | Completed | Phase 1/Phase 2 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases | March 2016 | January 2019 |
| NCT03250273 | Completed | Phase 2 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | November 6, 2017 | November 20, 2020 |
| NCT02939300 | Completed | Phase 2 | Ipilimumab and Nivolumab in Leptomeningeal Metastases | February 15, 2018 | July 22, 2021 |
| NCT03256136 | Completed | Phase 2 | Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC | November 22, 2017 | August 19, 2019 |
| NCT02935790 | Completed | Phase 1 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | September 30, 2016 | April 7, 2017 |
| NCT02935634 | Completed | Phase 2 | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | November 29, 2016 | May 11, 2022 |
| NCT02933255 | Completed | Phase 1/Phase 2 | PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | April 18, 2017 | December 1, 2023 |
| NCT03259529 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL | March 27, 2017 | January 27, 2020 |
| NCT04659551 | Completed | Phase 2 | Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | October 5, 2017 | May 25, 2020 |
| NCT03271047 | Completed | Phase 2 | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | October 18, 2017 | February 25, 2021 |
| NCT03126331 | Completed | Phase 2 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | August 3, 2017 | October 24, 2023 |
| NCT02913313 | Completed | Phase 1/Phase 2 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | November 30, 2016 | January 25, 2024 |
| NCT02905266 | Completed | Phase 3 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | October 27, 2016 | October 25, 2019 |
| NCT02904226 | Completed | Phase 1/Phase 2 | JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | August 2016 | July 1, 2020 |
| NCT03287674 | Completed | Phase 1/Phase 2 | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | October 9, 2017 | June 1, 2020 |
| NCT02903381 | Completed | Phase 2 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | October 20, 2016 | September 16, 2021 |
| NCT03294304 | Completed | Phase 2 | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | January 29, 2018 | July 1, 2021 |
| NCT02899299 | Completed | Phase 3 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | November 29, 2016 | April 28, 2023 |
| NCT02899078 | Completed | Phase 1/Phase 2 | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | November 15, 2016 | February 24, 2021 |
| NCT03299946 | Completed | Phase 1 | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | May 14, 2018 | October 1, 2021 |
| NCT02897765 | Completed | Phase 1 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | October 2016 | May 2020 |
| NCT02880020 | Completed | Phase 2 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | December 14, 2016 | August 9, 2022 |
| NCT03305445 | Completed | Phase 1 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | May 14, 2018 | April 1, 2021 |
| NCT03101566 | Completed | Phase 2 | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | September 8, 2017 | June 7, 2021 |
| NCT03310619 | Completed | Phase 1/Phase 2 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | December 20, 2017 | February 15, 2023 |
| NCT02866383 | Completed | Phase 2 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | November 2016 | November 30, 2022 |
| NCT02864381 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | September 1, 2016 | August 23, 2019 |
| NCT03316586 | Completed | Phase 2 | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | November 30, 2017 | August 30, 2019 |
| NCT02864251 | Completed | Phase 3 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | March 17, 2017 | October 17, 2022 |
| NCT03325816 | Completed | Phase 1/Phase 2 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | November 20, 2017 | August 11, 2020 |
| NCT02860546 | Completed | Phase 2 | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | August 29, 2016 | September 7, 2017 |
| NCT03329846 | Completed | Phase 3 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | November 30, 2017 | July 2, 2020 |
| NCT04907539 | Completed | Phase 2 | A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) | November 8, 2021 | April 2, 2024 |
| NCT02859324 | Completed | Phase 1/Phase 2 | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | September 20, 2016 | March 27, 2020 |
| NCT03335540 | Completed | Phase 1 | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | May 7, 2018 | August 25, 2021 |
| NCT03336216 | Completed | Phase 2 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | December 19, 2017 | June 1, 2023 |
| NCT02857426 | Completed | Phase 2 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | October 21, 2016 | November 24, 2020 |
| NCT02856451 | Completed | Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab | December 9, 2015 | December 31, 2020 | |
| NCT02848443 | Completed | Phase 1 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | May 2016 | April 9, 2020 |
| NCT02840994 | Completed | Phase 1 | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | December 2016 | January 2020 |
| NCT02837029 | Completed | Phase 1 | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | July 2016 | November 1, 2020 |
| NCT03342911 | Completed | Phase 2 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | November 13, 2017 | October 6, 2020 |
| NCT03343652 | Completed | Phase 1/Phase 2 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma | May 27, 2017 | March 27, 2020 |
| NCT02833233 | Completed | N/A | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer | June 2016 | June 7, 2024 |
| NCT02832167 | Completed | Phase 2 | An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread | February 22, 2016 | June 24, 2021 |
| NCT02829931 | Completed | Phase 1 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | August 22, 2016 | November 22, 2022 |
| NCT03349710 | Completed | Phase 3 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | December 15, 2017 | October 14, 2019 |
| NCT02829918 | Completed | Phase 2 | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers | October 5, 2016 | May 24, 2023 |
| NCT03353675 | Completed | Phase 2 | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | January 5, 2018 | February 17, 2021 |
| NCT02823990 | Completed | Phase 2 | TG4010 and Nivolumab in Patients With Lung Cancer | December 14, 2016 | February 24, 2021 |
| NCT02823574 | Completed | Phase 2 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | November 8, 2016 | April 21, 2022 |
| NCT03358719 | Completed | Phase 1 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | March 27, 2018 | August 25, 2021 |
| NCT02799901 | Completed | Phase 2 | Nivolumab Plus Radiotherapy in Advanced Melanoma | March 3, 2017 | July 28, 2021 |
| NCT02775292 | Completed | Phase 1 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | January 3, 2017 | April 8, 2019 |
| NCT03366766 | Completed | Phase 2 | Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | December 20, 2017 | February 8, 2023 |
| NCT03367715 | Completed | Phase 2 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | February 7, 2018 | March 17, 2022 |
| NCT02764593 | Completed | Phase 1 | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | June 2016 | February 21, 2022 |
| NCT02754141 | Completed | Phase 1/Phase 2 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | June 21, 2016 | October 12, 2021 |
| NCT02741570 | Completed | Phase 3 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | October 5, 2016 | September 22, 2022 |
| NCT02737787 | Completed | Phase 1 | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | April 2016 | April 6, 2023 |
| NCT02737475 | Completed | Phase 1/Phase 2 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | June 17, 2016 | November 2, 2020 |
| NCT03373188 | Completed | Phase 1 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | December 15, 2017 | October 28, 2021 |
| NCT04936399 | Completed | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom | June 25, 2020 | December 3, 2021 | |
| NCT02731729 | Completed | Phase 2 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | June 21, 2016 | February 13, 2019 |
| NCT03380130 | Completed | Phase 2 | A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC | September 11, 2017 | November 4, 2020 |
| NCT02726581 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma | August 10, 2016 | March 9, 2022 |
| NCT03130959 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | June 12, 2017 | January 17, 2022 |
| NCT02716948 | Completed | Phase 1 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | June 23, 2016 | August 27, 2021 |
| NCT02716272 | Completed | Phase 2 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients | March 24, 2016 | June 22, 2019 |
| NCT02713867 | Completed | Phase 3 | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks | May 24, 2016 | January 18, 2022 |
| NCT02684253 | Completed | Phase 2 | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | February 11, 2016 | January 22, 2021 |
| NCT02667587 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | May 9, 2016 | April 9, 2024 |
| NCT03387761 | Completed | Phase 1 | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | January 15, 2018 | September 13, 2021 |
| NCT04953962 | Completed | Phase 2 | Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer | December 18, 2021 | April 14, 2023 |
| NCT02659540 | Completed | Phase 1 | Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | October 13, 2016 | July 27, 2020 |
| NCT02659059 | Completed | Phase 2 | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer | February 15, 2016 | March 7, 2022 |
| NCT02658890 | Completed | Phase 1/Phase 2 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | April 14, 2016 | October 26, 2021 |
| NCT03396211 | Completed | Phase 1 | A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer | December 22, 2017 | March 16, 2022 |
| NCT02652455 | Completed | Early Phase 1 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | March 8, 2016 | August 30, 2020 |
| NCT02636036 | Completed | Phase 1 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors | January 25, 2016 | October 8, 2021 |
| NCT02631746 | Completed | Phase 2 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | February 21, 2017 | March 30, 2018 |
| NCT02631447 | Completed | Phase 2 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | November 14, 2016 | May 31, 2024 |
| NCT03406871 | Completed | Phase 1/Phase 2 | Regorafenib and Nivolumab Simultaneous Combination Therapy | January 25, 2018 | November 26, 2020 |
| NCT03409198 | Completed | Phase 2 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | January 21, 2018 | May 11, 2022 |
| NCT03409848 | Completed | Phase 2 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma | March 1, 2018 | March 5, 2022 |
| NCT03132038 | Completed | Phase 2 | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck | March 24, 2017 | October 20, 2021 |
| NCT03414983 | Completed | Phase 2/Phase 3 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread | February 20, 2018 | December 28, 2022 |
| NCT03416244 | Completed | Phase 2 | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer | February 21, 2018 | November 19, 2021 |
| NCT02626962 | Completed | Phase 2 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | April 2016 | July 22, 2021 |
| NCT03417154 | Completed | Phase 2 | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | August 13, 2018 | January 25, 2022 |
| NCT03418922 | Completed | Phase 1 | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | January 30, 2018 | December 28, 2022 |
| NCT02617589 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | March 1, 2016 | March 4, 2022 |
| NCT03421652 | Completed | Phase 2 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | April 24, 2018 | March 23, 2023 |
| NCT02613507 | Completed | Phase 3 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer | December 11, 2015 | May 31, 2023 |
| NCT03425292 | Completed | Phase 1 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | March 1, 2018 | October 27, 2023 |
| NCT02612779 | Completed | Phase 2 | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | February 9, 2016 | June 12, 2020 |
| NCT02601014 | Completed | Phase 2 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | March 15, 2016 | October 6, 2021 |
| NCT03431948 | Completed | Phase 1 | Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer | March 15, 2018 | April 11, 2022 |
| NCT02599402 | Completed | Phase 3 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | December 20, 2015 | February 10, 2020 |
| NCT02598960 | Completed | Phase 1/Phase 2 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | October 14, 2015 | December 16, 2019 |
| NCT03436862 | Completed | Phase 2 | Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk | May 23, 2018 | April 4, 2023 |
| NCT02596035 | Completed | Phase 4 | An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma | January 8, 2016 | May 24, 2021 |
| NCT02593786 | Completed | Phase 1/Phase 2 | A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors | January 7, 2016 | September 27, 2021 |
| NCT02581631 | Completed | Phase 1/Phase 2 | An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas | February 11, 2016 | February 7, 2022 |
| NCT02576509 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | December 7, 2015 | February 7, 2024 |
| NCT03444766 | Completed | Phase 4 | Study of Nivolumab for Advanced Cancers in India | March 6, 2018 | July 17, 2019 |
| NCT02575222 | Completed | Phase 1 | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | February 2016 | June 9, 2020 |
| NCT02574078 | Completed | Phase 1/Phase 2 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | November 23, 2015 | April 15, 2020 |
| NCT03098550 | Completed | Phase 1/Phase 2 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | June 15, 2017 | July 6, 2020 |
| NCT03451331 | Completed | Phase 2 | Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer | May 10, 2018 | July 28, 2023 |
| NCT02572167 | Completed | Phase 1/Phase 2 | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | October 31, 2015 | October 21, 2021 |
| NCT03453892 | Completed | Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | April 1, 2017 | December 30, 2022 | |
| NCT02569242 | Completed | Phase 3 | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | December 14, 2015 | October 23, 2020 |
| NCT02553642 | Completed | Phase 2 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | September 14, 2015 | April 29, 2024 |
| NCT02550249 | Completed | Phase 2 | Neoadjuvant Nivolumab in Glioblastoma | June 2015 | March 2017 |
| NCT02538666 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | October 13, 2015 | November 11, 2021 |
| NCT03468985 | Completed | Phase 2 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | May 7, 2018 | December 21, 2022 |
| NCT03469713 | Completed | Phase 2 | Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma | July 14, 2017 | July 14, 2021 |
| NCT02534506 | Completed | Phase 1 | Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | November 6, 2015 | November 11, 2016 |
| NCT02532231 | Completed | Phase 2 | Nivolumab in AML in Remission at High Risk for Relapse | October 19, 2015 | August 8, 2023 |
| NCT03136627 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | March 22, 2017 | June 18, 2021 |
| NCT05005273 | Completed | Phase 2 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | October 3, 2022 | December 27, 2022 |
| NCT02529072 | Completed | Phase 1 | Nivolumab With DC Vaccines for Recurrent Brain Tumors | January 2016 | December 30, 2019 |
| NCT03486119 | Completed | A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients | February 5, 2018 | July 7, 2020 | |
| NCT02526017 | Completed | Phase 1 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | September 8, 2015 | November 18, 2019 |
| NCT03493932 | Completed | Phase 1 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | September 24, 2018 | June 27, 2023 |
| NCT02523469 | Completed | Phase 1/Phase 2 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | January 8, 2016 | February 24, 2023 |
| NCT02519322 | Completed | Phase 2 | Neoadjuvant and Adjuvant Checkpoint Blockade | February 2, 2016 | January 26, 2023 |
| NCT02518958 | Completed | Phase 1 | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab | July 21, 2015 | September 12, 2016 |
| NCT02500797 | Completed | Phase 2 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | August 13, 2015 | April 1, 2023 |
| NCT02497508 | Completed | Phase 2 | Nivolumab in Patients With Recurrent Malignant Mesothelioma | July 2015 | July 2017 |
| NCT02488759 | Completed | Phase 1/Phase 2 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | October 13, 2015 | October 24, 2022 |
| NCT02483247 | Completed | Phase 1 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | September 2015 | May 2019 |
| NCT02481830 | Completed | Phase 3 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | September 14, 2015 | August 30, 2022 |
| NCT06361563 | Completed | Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada | September 5, 2023 | January 25, 2024 | |
| NCT05471674 | Completed | Phase 2 | Neoadjuvant Anti-PD1 in HCC | July 3, 2020 | December 31, 2022 |
| NCT03927105 | Completed | Phase 2 | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | April 25, 2019 | July 6, 2023 |
| NCT03785210 | Completed | Phase 2 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | June 5, 2019 | December 31, 2022 |
| NCT03785925 | Completed | Phase 2 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | April 29, 2019 | June 30, 2022 |
| NCT02467361 | Completed | Phase 1 | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | August 2015 | January 29, 2021 |
| NCT02464657 | Completed | Phase 1/Phase 2 | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | July 2015 | May 7, 2020 |
| NCT02439450 | Completed | Phase 1/Phase 2 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | April 15, 2015 | November 4, 2022 |
| NCT05041062 | Completed | Phase 2 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | December 1, 2021 | April 13, 2023 |
| NCT02434081 | Completed | Phase 2 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma | November 25, 2015 | March 31, 2020 |
| NCT01176474 | Completed | Phase 1 | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | August 13, 2010 | January 6, 2023 |
| NCT02426892 | Completed | Phase 2 | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | December 23, 2015 | November 30, 2021 |
| NCT03525925 | Completed | Phase 1 | Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors | July 18, 2018 | July 31, 2022 |
| NCT02423343 | Completed | Phase 1/Phase 2 | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | January 1, 2015 | July 8, 2020 |
| NCT05061017 | Completed | Phase 2 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | December 9, 2021 | March 18, 2024 |
| NCT02420912 | Completed | Phase 2 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | June 19, 2015 | February 14, 2022 |
| NCT03532217 | Completed | Phase 1 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | September 14, 2018 | July 25, 2022 |
| NCT03532451 | Completed | Phase 1 | Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | March 22, 2019 | October 5, 2022 |
| NCT05068609 | Completed | A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) | August 13, 2020 | October 18, 2021 | |
| NCT02419417 | Completed | Phase 1/Phase 2 | Study of BMS-986158 in Subjects With Select Advanced Cancers | June 19, 2015 | March 17, 2021 |
| NCT02409368 | Completed | Phase 2 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | April 29, 2015 | August 27, 2021 |
| NCT02397720 | Completed | Phase 2 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | April 7, 2015 | October 9, 2023 |
| NCT05081674 | Completed | Phase 2 | Brazilian Lung Immunotherapy Study | January 1, 2020 | July 30, 2023 |
| NCT02387996 | Completed | Phase 2 | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | March 9, 2015 | November 12, 2021 |
| NCT03554317 | Completed | Phase 2 | COMbination of Bipolar Androgen Therapy and Nivolumab | September 5, 2018 | January 6, 2023 |
| NCT04540705 | Completed | Phase 1 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | September 11, 2020 | January 18, 2024 |
| NCT03558087 | Completed | Phase 2 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | July 13, 2018 | March 7, 2024 |
| NCT02350764 | Completed | Phase 2 | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | January 20, 2015 | September 25, 2023 |
| NCT02339558 | Completed | Phase 2 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | July 21, 2015 | |
| NCT02329847 | Completed | Phase 1/Phase 2 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | March 11, 2015 | February 9, 2022 |
| NCT03565445 | Completed | Phase 1 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | July 2, 2018 | March 27, 2023 |
| NCT02327078 | Completed | Phase 1/Phase 2 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | November 26, 2014 | June 16, 2020 |
| NCT02320058 | Completed | Phase 2 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself | March 5, 2015 | September 8, 2020 |
| NCT02311920 | Completed | Phase 1 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | April 16, 2015 | December 22, 2022 |
| NCT03572582 | Completed | Phase 2 | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma | June 14, 2018 | December 10, 2021 |
| NCT03573947 | Completed | Phase 2 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | October 2, 2018 | June 15, 2023 |
| NCT02309177 | Completed | Phase 1 | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | January 12, 2015 | September 12, 2018 |
| NCT03575598 | Completed | Early Phase 1 | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study | August 30, 2018 | February 18, 2020 |
| NCT02304458 | Completed | Phase 1/Phase 2 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | March 30, 2015 | March 31, 2023 |
| NCT04518046 | Completed | Phase 1 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | August 11, 2020 | June 30, 2023 |
| NCT02247349 | Completed | Phase 1/Phase 2 | BMS-986012 in Relapsed/Refractory SCLC | November 14, 2014 | December 22, 2022 |
| NCT02243371 | Completed | Phase 2 | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | January 2, 2015 | July 21, 2017 |
| NCT03580408 | Completed | Phase 2 | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma | August 31, 2018 | August 12, 2021 |
| NCT05116202 | Completed | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | February 2, 2022 | March 27, 2024 |
| NCT04513522 | Completed | Phase 4 | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India | December 17, 2020 | January 4, 2024 |
| NCT02213289 | Completed | Phase 2 | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | January 20, 2015 | August 20, 2020 |
| NCT03590210 | Completed | Phase 2 | Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas | June 8, 2018 | February 12, 2022 |
| NCT02181738 | Completed | Phase 2 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | August 12, 2014 | December 27, 2022 |
| NCT02154490 | Completed | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | July 8, 2014 | April 15, 2022 | |
| NCT02118337 | Completed | Phase 1/Phase 2 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | May 19, 2014 | March 17, 2020 |
| NCT02105636 | Completed | Phase 3 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | May 29, 2014 | September 10, 2021 |
| NCT02073123 | Completed | Phase 1/Phase 2 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | July 2014 | July 3, 2019 |
| NCT02066636 | Completed | Phase 3 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen | April 9, 2014 | October 6, 2021 |
| NCT02041533 | Completed | Phase 3 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | March 27, 2014 | May 27, 2022 |
| NCT03605719 | Completed | Phase 1 | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | October 24, 2018 | October 10, 2022 |
| NCT02038946 | Completed | Phase 2 | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | March 26, 2014 | December 28, 2020 |
| NCT02038933 | Completed | Phase 2 | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | March 5, 2014 | October 8, 2020 |
| NCT03090737 | Completed | Phase 2 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer | June 2, 2017 | March 14, 2022 |
| NCT03618641 | Completed | Phase 2 | CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | August 8, 2018 | December 31, 2023 |
| NCT03620019 | Completed | Phase 2 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | September 25, 2018 | August 15, 2023 |
| NCT03623854 | Completed | Phase 2 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | April 3, 2019 | September 28, 2023 |
| NCT02011945 | Completed | Phase 1 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | February 7, 2014 | December 26, 2018 |
| NCT01998126 | Completed | Phase 1 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | December 2, 2013 | March 29, 2018 |
| NCT03633110 | Completed | Phase 1/Phase 2 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | August 29, 2018 | February 28, 2022 |
| NCT01928576 | Completed | Phase 2 | Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | November 6, 2013 | April 4, 2023 |
| NCT03635983 | Completed | Phase 3 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | September 21, 2018 | September 6, 2023 |
| NCT03636477 | Completed | Phase 1 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | June 18, 2018 | June 30, 2021 |
| NCT05169684 | Completed | Phase 2 | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | February 14, 2022 | December 6, 2023 |
| NCT03639714 | Completed | Phase 1/Phase 2 | A Study of a Personalized Neoantigen Cancer Vaccine | February 13, 2019 | November 10, 2022 |
| NCT01927419 | Completed | Phase 2 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma | August 23, 2013 | February 26, 2021 |
| NCT01822509 | Completed | Phase 1 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | May 16, 2013 | June 10, 2021 |
| NCT01783938 | Completed | Phase 2 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | April 30, 2013 | August 12, 2020 |
| NCT03068455 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma | April 11, 2017 | February 2, 2021 |
| NCT01721759 | Completed | Phase 2 | Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens | November 16, 2012 | April 22, 2021 |
| NCT01716806 | Completed | Phase 2 | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | October 31, 2012 | September 12, 2023 |
| NCT01714739 | Completed | Phase 1/Phase 2 | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | October 7, 2012 | December 13, 2019 |
| NCT01673867 | Completed | Phase 3 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | November 2, 2012 | December 17, 2021 |
| NCT01668784 | Completed | Phase 3 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | October 9, 2012 | July 19, 2021 |
| NCT01642004 | Completed | Phase 3 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | October 16, 2012 | August 16, 2021 |
| NCT01629758 | Completed | Phase 1 | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | June 2012 | December 2014 |
| NCT01621490 | Completed | Phase 1 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | September 27, 2012 | October 25, 2018 |
| NCT01585194 | Completed | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | November 29, 2012 | May 14, 2024 |
| NCT01472081 | Completed | Phase 1 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | February 9, 2012 | June 3, 2021 |
| NCT03138512 | Completed | Phase 3 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney | July 7, 2017 | February 1, 2024 |
| NCT01454102 | Completed | Phase 1 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | December 16, 2011 | July 23, 2021 |
| NCT03661632 | Completed | Phase 1 | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | September 11, 2018 | December 29, 2020 |
| NCT01354431 | Completed | Phase 2 | BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) | May 31, 2011 | April 15, 2021 |
| NCT03662659 | Completed | Phase 2 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | October 16, 2018 | January 18, 2024 |
| NCT04439214 | Completed | Phase 2 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | May 31, 2016 | May 17, 2020 |
| NCT03668119 | Completed | Phase 2 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | October 31, 2018 | August 2, 2023 |
| NCT03680521 | Completed | Phase 2 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | October 10, 2018 | May 18, 2023 |
| NCT04393220 | Completed | Phase 2 | Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma | May 11, 2020 | August 31, 2021 |
| NCT04382664 | Completed | Phase 2 | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | June 15, 2020 | April 10, 2024 |
| NCT03684811 | Completed | Phase 1/Phase 2 | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | November 1, 2018 | June 13, 2022 |
| NCT04350463 | Completed | Phase 2 | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | July 14, 2020 | December 19, 2023 |
| NCT04322643 | Completed | Phase 2 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | March 23, 2020 | April 17, 2023 |
| NCT04299880 | Completed | Phase 1 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | February 24, 2020 | May 30, 2021 |
| NCT04271384 | Completed | Phase 2 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | February 12, 2020 | November 15, 2023 |
| NCT04263090 | Completed | Phase 1/Phase 2 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | June 29, 2020 | December 20, 2023 |
| NCT04209114 | Completed | Phase 3 | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer | February 5, 2020 | June 7, 2023 |
| NCT04208958 | Completed | Phase 1/Phase 2 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer | January 23, 2020 | February 23, 2023 |
| NCT05714371 | Completed | Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | October 2, 2021 | January 27, 2022 | |
| NCT04197310 | Completed | Phase 2 | Cabozantinib and Nivolumab for Carcinoid Tumors | December 26, 2019 | January 31, 2024 |
| NCT03711188 | Completed | Phase 2 | A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | October 4, 2018 | December 2, 2021 |
| NCT03061188 | Completed | Phase 1 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | May 23, 2017 | August 4, 2020 |
| NCT03712943 | Completed | Phase 1 | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer | October 23, 2018 | January 18, 2024 |
| NCT04187833 | Completed | Phase 2 | Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes | June 5, 2020 | October 13, 2023 |
| NCT04166383 | Completed | Phase 2 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | August 9, 2020 | December 31, 2022 |
| NCT04132817 | Completed | Phase 1 | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread | September 22, 2020 | August 15, 2022 |
| NCT04124601 | Completed | Phase 2 | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer | June 1, 2020 | March 15, 2024 |
| NCT04123925 | Completed | Phase 2 | Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study | June 12, 2018 | September 2, 2019 |
| NCT04123379 | Completed | Phase 2 | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | March 5, 2020 | November 16, 2023 |
| NCT04122625 | Completed | Phase 1/Phase 2 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | April 26, 2019 | April 6, 2022 |
| NCT04118166 | Completed | Phase 2 | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | October 1, 2019 | April 26, 2022 |
| NCT03735628 | Completed | Phase 1 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | October 17, 2018 | October 13, 2022 |
| NCT04112498 | Completed | Phase 1 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | October 1, 2019 | February 27, 2023 |
| NCT04109066 | Completed | Phase 3 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | November 20, 2019 | December 27, 2023 |
| NCT04098432 | Completed | Phase 1/Phase 2 | Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma | December 3, 2018 | September 30, 2022 |
| NCT03745807 | Completed | Phase 1 | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | April 9, 2019 | December 18, 2019 |
| NCT04091490 | Completed | Phase 2 | Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) | February 19, 2020 | December 31, 2022 |
| NCT03749460 | Completed | Phase 1/Phase 2 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | January 15, 2019 | November 5, 2023 |
| NCT04084951 | Completed | Phase 1 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | January 28, 2020 | February 9, 2023 |
| NCT03758781 | Completed | Phase 1 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | February 13, 2019 | August 11, 2021 |
| NCT04075604 | Completed | Phase 2 | A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | October 18, 2019 | July 27, 2021 |
| NCT04050085 | Completed | Phase 1 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | August 15, 2019 | May 14, 2022 |
| NCT05611229 | Completed | Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | June 16, 2020 | December 3, 2021 | |
| NCT05498480 | Completed | Phase 1 | Study of Relatlimab in Combination With Nivolumab in Chinese Participants | July 27, 2022 | January 18, 2024 |
| NCT03980314 | Completed | Phase 1 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | June 24, 2019 | November 6, 2023 |
| NCT03980041 | Completed | Phase 2 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | September 25, 2019 | November 15, 2022 |
| NCT03956680 | Completed | Phase 1 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | March 26, 2019 | April 17, 2024 |
| NCT05297565 | Completed | Phase 3 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection | August 3, 2022 | February 8, 2024 |
| NCT03953235 | Completed | Phase 1/Phase 2 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | July 18, 2019 | March 10, 2023 |
| NCT05745233 | Enrolling by invitation | N/A | Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites | January 1, 2021 | December 2026 |
| NCT02475382 | No longer available | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen | |||
| NCT02142218 | No longer available | Expanded Access Program With Nivolumab to Treat Melanoma | June 2014 | May 2018 | |
| NCT02186249 | No longer available | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma | |||
| NCT05887830 | Not yet recruiting | Phase 1/Phase 2 | Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial | June 15, 2023 | December 31, 2025 |
| NCT06163820 | Not yet recruiting | Phase 1/Phase 2 | Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | January 30, 2024 | January 30, 2026 |
| NCT06204614 | Not yet recruiting | Early Phase 1 | Drug Screening Using IMD in Bladder Cancer | February 14, 2024 | July 1, 2025 |
| NCT06240143 | Not yet recruiting | Phase 1/Phase 2 | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | February 2024 | May 2026 |
| NCT06245356 | Not yet recruiting | Phase 2 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | June 20, 2024 | June 21, 2028 |
| NCT04910347 | Not yet recruiting | Phase 2 | A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | June 2021 | December 2025 |
| NCT06253611 | Not yet recruiting | Phase 2 | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | March 2024 | March 2029 |
| NCT06264180 | Not yet recruiting | Phase 3 | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) | June 1, 2024 | August 31, 2034 |
| NCT06274437 | Not yet recruiting | Phase 1 | A Study of BND-35 in Participants With Advanced Solid Tumors | April 2024 | November 2027 |
| NCT06284564 | Not yet recruiting | Phase 2 | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | September 30, 2024 | October 1, 2026 |
| NCT06302426 | Not yet recruiting | Phase 1 | Trial of INI-4001 in Patients With Advanced Solid Tumours | March 29, 2024 | April 30, 2026 |
| NCT06325683 | Not yet recruiting | Phase 2 | Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | August 16, 2024 | July 15, 2028 |
| NCT06346197 | Not yet recruiting | Phase 3 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | May 15, 2024 | May 15, 2028 |
| NCT06357858 | Not yet recruiting | Phase 1 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | June 1, 2024 | February 28, 2026 |
| NCT06364917 | Not yet recruiting | Phase 2 | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | October 31, 2024 | June 2027 |
| NCT06365619 | Not yet recruiting | Phase 2 | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | August 2024 | August 2029 |
| NCT05457959 | Not yet recruiting | Phase 1 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | December 1, 2024 | May 1, 2030 |
| NCT05461235 | Not yet recruiting | Phase 2 | Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | July 15, 2022 | December 1, 2025 |
| NCT06377111 | Not yet recruiting | Phase 1 | A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma | May 2024 | May 2026 |
| NCT05588297 | Not yet recruiting | Phase 2 | Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases | October 2022 | October 2025 |
| NCT05629546 | Not yet recruiting | Phase 1 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | June 30, 2024 | June 30, 2030 |
| NCT06410534 | Not yet recruiting | Phase 2 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | June 23, 2024 | September 1, 2032 |
| NCT06421311 | Not yet recruiting | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France | June 15, 2024 | May 1, 2028 | |
| NCT05717140 | Not yet recruiting | Phase 1 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | June 2024 | April 2025 |
| NCT05088889 | Recruiting | Phase 1 | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | January 25, 2022 | July 1, 2024 |
| NCT05931393 | Recruiting | Phase 2 | Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) | December 20, 2023 | December 31, 2027 |
| NCT04561206 | Recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | November 12, 2021 | October 2, 2024 |
| NCT03546686 | Recruiting | Phase 2 | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | November 12, 2019 | June 2026 |
| NCT04912765 | Recruiting | Phase 2 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | April 15, 2021 | May 2025 |
| NCT02408861 | Recruiting | Phase 1 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | October 21, 2015 | July 1, 2024 |
| NCT05076760 | Recruiting | Phase 1 | MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer | February 23, 2022 | November 2026 |
| NCT03543969 | Recruiting | Early Phase 1 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | June 14, 2018 | July 2028 |
| NCT04562129 | Recruiting | Phase 2 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | September 24, 2020 | September 2029 |
| NCT03340129 | Recruiting | Phase 2 | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | August 14, 2019 | August 2025 |
| NCT04013854 | Recruiting | Phase 2 | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | January 1, 2020 | August 2026 |
| NCT03527108 | Recruiting | Phase 2 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | October 8, 2020 | April 2026 |
| NCT04015778 | Recruiting | Phase 2 | A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | August 8, 2019 | July 2024 |
| NCT04913025 | Recruiting | Phase 2 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers | May 26, 2022 | April 2025 |
| NCT05048212 | Recruiting | Phase 2 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | September 20, 2022 | July 31, 2024 |
| NCT03521830 | Recruiting | Phase 2 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | November 27, 2018 | March 2027 |
| NCT03520491 | Recruiting | Phase 2 | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | April 25, 2018 | January 2025 |
| NCT06031233 | Recruiting | Phase 4 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | September 1, 2023 | December 2024 |
| NCT02451982 | Recruiting | Phase 2 | Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | March 28, 2016 | December 31, 2025 |
| NCT05987241 | Recruiting | Phase 2/Phase 3 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study | February 2, 2024 | April 11, 2026 |
| NCT04017650 | Recruiting | Phase 1/Phase 2 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | June 14, 2019 | June 30, 2025 |
| NCT04572451 | Recruiting | Phase 1 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | November 29, 2021 | May 31, 2027 |
| NCT04913922 | Recruiting | Phase 2 | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | May 5, 2021 | March 2026 |
| NCT04019964 | Recruiting | Phase 2 | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | January 13, 2020 | January 2025 |
| NCT05500092 | Recruiting | Phase 2 | An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer | January 25, 2023 | July 2025 |
| NCT05501054 | Recruiting | Phase 1/Phase 2 | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | February 9, 2023 | November 1, 2026 |
| NCT05987332 | Recruiting | Phase 2/Phase 3 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | October 31, 2023 | January 15, 2028 |
| NCT04810078 | Recruiting | Phase 3 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | May 24, 2021 | January 29, 2026 |
| NCT04925284 | Recruiting | Phase 1 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | June 7, 2021 | October 7, 2024 |
| NCT03505320 | Recruiting | Phase 2 | A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma | June 29, 2018 | December 31, 2026 |
| NCT06003075 | Recruiting | Phase 2 | Induction Chemo-Nivo in Unresectable Stage III NSCLC | September 22, 2023 | August 2027 |
| NCT05921760 | Recruiting | Phase 1/Phase 2 | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | October 23, 2023 | March 2026 |
| NCT03576417 | Recruiting | Phase 3 | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | October 10, 2018 | September 2027 |
| NCT04525638 | Recruiting | Phase 2 | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | June 29, 2020 | September 30, 2024 |
| NCT05926960 | Recruiting | Phase 2 | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | June 13, 2023 | May 23, 2027 |
| NCT05111626 | Recruiting | Phase 3 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer | March 14, 2022 | September 26, 2026 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT06094296 | Recruiting | Phase 2 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | November 27, 2023 | October 27, 2027 |
| NCT04535713 | Recruiting | Phase 2 | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | September 30, 2020 | December 31, 2025 |
| NCT05111574 | Recruiting | Phase 2 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | August 11, 2022 | December 19, 2024 |
| NCT04003649 | Recruiting | Phase 1 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | December 2, 2019 | July 31, 2025 |
| NCT06034860 | Recruiting | Phase 1 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | November 1, 2023 | October 2026 |
| NCT05098210 | Recruiting | Phase 1 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | June 9, 2022 | November 1, 2025 |
| NCT06116461 | Recruiting | Phase 4 | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response | January 5, 2022 | January 2025 |
| NCT02339571 | Recruiting | Phase 2/Phase 3 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | November 23, 2015 | June 30, 2033 |
| NCT04008030 | Recruiting | Phase 3 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | August 5, 2019 | June 10, 2026 |
| NCT03313544 | Recruiting | Phase 4 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | April 9, 2018 | March 2025 |
| NCT03317327 | Recruiting | Phase 1/Phase 2 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors | September 9, 2017 | November 2, 2040 |
| NCT05928806 | Recruiting | Phase 2 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | September 25, 2023 | October 12, 2026 |
| NCT06015724 | Recruiting | Phase 2 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | January 31, 2024 | January 2026 |
| NCT05502315 | Recruiting | Phase 2 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | February 2, 2023 | October 12, 2024 |
| NCT05039073 | Recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | May 2, 2022 | November 30, 2027 |
| NCT05034536 | Recruiting | Phase 2 | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | February 7, 2022 | June 30, 2026 |
| NCT04929028 | Recruiting | Phase 2 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | August 9, 2022 | September 15, 2029 |
| NCT05504252 | Recruiting | Phase 2 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin | October 5, 2022 | December 30, 2027 |
| NCT02817633 | Recruiting | Phase 1 | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | July 8, 2016 | April 27, 2027 |
| NCT05012254 | Recruiting | Phase 2 | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | November 18, 2021 | December 15, 2026 |
| NCT04599140 | Recruiting | Phase 1/Phase 2 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | October 14, 2020 | January 31, 2025 |
| NCT04991025 | Recruiting | Phase 2 | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | October 19, 2022 | October 2024 |
| NCT04989946 | Recruiting | Phase 1/Phase 2 | Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | December 16, 2021 | December 2028 |
| NCT03465592 | Recruiting | Phase 1/Phase 2 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | May 1, 2018 | March 2029 |
| NCT04988841 | Recruiting | Phase 2 | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma | January 20, 2022 | June 1, 2024 |
| NCT06101134 | Recruiting | Phase 2 | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | November 8, 2023 | August 31, 2027 |
| NCT06275360 | Recruiting | Phase 2 | Repositioning Immunotherapy in VetArans With Lung Cancer | March 1, 2024 | March 31, 2030 |
| NCT04981899 | Recruiting | Phase 1/Phase 2 | A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma | March 1, 2021 | October 1, 2024 |
| NCT06265285 | Recruiting | Phase 2 | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | March 13, 2024 | December 31, 2026 |
| NCT04966676 | Recruiting | Phase 2 | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer | January 24, 2022 | November 1, 2025 |
| NCT06399419 | Recruiting | Phase 1 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | June 19, 2024 | October 19, 2026 |
| NCT04966663 | Recruiting | Phase 2 | Using ctDNA to Determine Therapies for Lung Cancer | March 28, 2022 | December 1, 2026 |
| NCT02813135 | Recruiting | Phase 1/Phase 2 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | August 3, 2016 | August 2027 |
| NCT04929041 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | October 7, 2022 | December 31, 2027 |
| NCT05347212 | Recruiting | Phase 2 | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | September 22, 2022 | July 16, 2027 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT03047928 | Recruiting | Phase 1/Phase 2 | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | February 22, 2018 | April 1, 2023 |
| NCT05407441 | Recruiting | Phase 1/Phase 2 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | August 10, 2023 | February 1, 2029 |
| NCT04817254 | Recruiting | Phase 2 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | December 8, 2021 | December 31, 2026 |
| NCT03767582 | Recruiting | Phase 1/Phase 2 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | December 12, 2019 | December 31, 2024 |
| NCT04759586 | Recruiting | Phase 3 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | October 5, 2021 | September 30, 2027 |
| NCT04930783 | Recruiting | Phase 1 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | January 3, 2022 | January 31, 2027 |
| NCT04620200 | Recruiting | Phase 2 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery | August 11, 2020 | November 1, 2024 |
| NCT05625412 | Recruiting | Phase 1 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | December 9, 2022 | July 30, 2027 |
| NCT03406247 | Recruiting | Phase 2 | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | February 12, 2018 | May 2026 |
| NCT06019130 | Recruiting | Phase 2 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | January 10, 2023 | January 9, 2028 |
| NCT06362369 | Recruiting | Phase 1/Phase 2 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | May 20, 2024 | December 31, 2028 |
| NCT04957615 | Recruiting | Phase 2 | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | September 21, 2021 | May 31, 2027 |
| NCT04612530 | Recruiting | Phase 1 | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | September 1, 2020 | June 1, 2023 |
| NCT04933903 | Recruiting | Phase 2 | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | October 5, 2021 | January 2025 |
| NCT04823403 | Recruiting | Phase 1 | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | November 13, 2020 | November 2024 |
| NCT06250335 | Recruiting | Phase 2 | Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients | March 1, 2024 | January 23, 2029 |
| NCT04609046 | Recruiting | Phase 1 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | May 24, 2021 | May 31, 2025 |
| NCT03391869 | Recruiting | Phase 3 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | December 29, 2017 | December 31, 2025 |
| NCT06256328 | Recruiting | Phase 2 | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | December 6, 2023 | December 31, 2027 |
| NCT03388632 | Recruiting | Phase 1 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | February 5, 2018 | December 1, 2024 |
| NCT06064097 | Recruiting | Phase 2 | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | January 17, 2025 | August 31, 2026 |
| NCT06029270 | Recruiting | Phase 2 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | October 4, 2024 | April 30, 2029 |
| NCT04061980 | Recruiting | Phase 2 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | October 30, 2020 | October 30, 2026 |
| NCT04953104 | Recruiting | Phase 2 | Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | September 21, 2021 | December 31, 2024 |
| NCT05341349 | Recruiting | Phase 1 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | October 13, 2022 | March 6, 2025 |
| NCT03811015 | Recruiting | Phase 3 | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | August 16, 2019 | January 1, 2027 |
| NCT03033914 | Recruiting | Phase 1/Phase 2 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | January 25, 2017 | January 2026 |
| NCT03767348 | Recruiting | Phase 2 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | September 20, 2017 | November 2024 |
| NCT05633667 | Recruiting | Phase 2 | Study of Novel Treatment Combinations in Patients With Lung Cancer | March 16, 2023 | January 2027 |
| NCT05647265 | Recruiting | Phase 2 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | March 14, 2023 | December 15, 2024 |
| NCT04080804 | Recruiting | Phase 2 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | January 8, 2020 | September 30, 2027 |
| NCT05652673 | Recruiting | N/A | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | February 1, 2023 | December 1, 2029 |
| NCT05423262 | Recruiting | Phase 1 | A Study of TRK-950 in Patients With Advanced Solid Tumors | July 6, 2022 | February 2025 |
| NCT05263050 | Recruiting | Phase 2 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | January 21, 2022 | February 2027 |
| NCT04095208 | Recruiting | Phase 2 | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study | February 27, 2020 | December 2025 |
| NCT05255601 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | September 13, 2022 | July 5, 2028 |
| NCT05660993 | Recruiting | Phase 2 | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma | August 19, 2019 | March 1, 2025 |
| NCT03026140 | Recruiting | Phase 2 | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | March 29, 2017 | December 2024 |
| NCT05672173 | Recruiting | Phase 2 | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | June 2, 2023 | September 10, 2025 |
| NCT04107168 | Recruiting | Microbiome Immunotherapy Toxicity and Response Evaluation | July 8, 2020 | July 8, 2025 | |
| NCT05239533 | Recruiting | Phase 2 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | February 16, 2022 | March 2025 |
| NCT04109729 | Recruiting | Phase 1/Phase 2 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer | August 25, 2020 | April 30, 2026 |
| NCT04745949 | Recruiting | Phase 2 | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | May 10, 2021 | August 3, 2025 |
| NCT04117087 | Recruiting | Phase 1 | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | May 28, 2020 | August 8, 2025 |
| NCT05317000 | Recruiting | Early Phase 1 | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC | March 23, 2023 | February 2026 |
| NCT05310643 | Recruiting | Phase 2 | Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy | May 5, 2022 | September 30, 2027 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT05234307 | Recruiting | Phase 1 | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | November 21, 2022 | December 31, 2025 |
| NCT03727061 | Recruiting | Phase 1 | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | July 10, 2019 | December 10, 2024 |
| NCT04741997 | Recruiting | Early Phase 1 | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | May 24, 2021 | January 2027 |
| NCT06059547 | Recruiting | Phase 2 | Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer | September 6, 2023 | August 31, 2025 |
| NCT05675410 | Recruiting | Phase 3 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | May 11, 2023 | April 28, 2031 |
| NCT06132945 | Recruiting | Phase 1 | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | November 10, 2023 | November 2027 |
| NCT03815890 | Recruiting | Phase 2 | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | October 4, 2019 | January 1, 2033 |
| NCT05677490 | Recruiting | Phase 3 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | January 23, 2023 | November 8, 2028 |
| NCT03166397 | Recruiting | Phase 2 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | June 5, 2017 | June 1, 2026 |
| NCT04134325 | Recruiting | Early Phase 1 | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | September 1, 2019 | July 7, 2037 |
| NCT04143711 | Recruiting | Phase 1/Phase 2 | Study of DF1001 in Patients With Advanced Solid Tumors | November 11, 2019 | December 2026 |
| NCT05678673 | Recruiting | Phase 3 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | January 1, 2023 | June 2028 |
| NCT06054555 | Recruiting | Phase 3 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | November 2, 2023 | January 25, 2027 |
| NCT06364631 | Recruiting | Phase 3 | CARE1 Pragmatic Clinical Trial | April 12, 2024 | May 5, 2032 |
| NCT04150640 | Recruiting | Phase 2 | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | July 13, 2020 | December 2026 |
| NCT04840589 | Recruiting | Phase 1 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | February 2, 2022 | January 1, 2026 |
| NCT04159818 | Recruiting | Phase 2 | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | February 21, 2020 | December 15, 2026 |
| NCT04159896 | Recruiting | Phase 2 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | November 13, 2019 | March 1, 2022 |
| NCT05681780 | Recruiting | Phase 1/Phase 2 | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | January 23, 2023 | July 2025 |
| NCT06053658 | Recruiting | Phase 2 | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | January 5, 2024 | November 1, 2028 |
| NCT05684276 | Recruiting | Phase 2 | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors | May 12, 2023 | June 1, 2028 |
| NCT04709276 | Recruiting | Phase 2 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer | June 7, 2021 | June 2027 |
| NCT04180371 | Recruiting | Phase 1/Phase 2 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | November 7, 2019 | December 31, 2024 |
| NCT05343481 | Recruiting | Phase 2 | Efficacy of VTP-300 in Chronic Hepatitis B Infection | September 21, 2022 | August 2024 |
| NCT05704647 | Recruiting | Phase 2 | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases | February 23, 2023 | December 31, 2026 |
| NCT03718767 | Recruiting | Phase 2 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | March 27, 2019 | February 27, 2026 |
| NCT05445609 | Recruiting | Phase 2 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | June 7, 2023 | June 23, 2027 |
| NCT05219435 | Recruiting | Phase 2 | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | July 6, 2022 | December 2025 |
| NCT04204837 | Recruiting | Phase 2 | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | March 6, 2017 | December 2027 |
| NCT05337137 | Recruiting | Phase 1/Phase 2 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | May 5, 2022 | December 15, 2026 |
| NCT03173950 | Recruiting | Phase 2 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | July 13, 2017 | April 21, 2027 |
| NCT04702880 | Recruiting | Phase 2 | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | March 17, 2021 | December 31, 2025 |
| NCT05361720 | Recruiting | Phase 2 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | December 1, 2022 | July 1, 2026 |
| NCT04229459 | Recruiting | Phase 2 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | December 30, 2019 | June 2027 |
| NCT04697576 | Recruiting | Phase 1 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | October 20, 2021 | December 31, 2025 |
| NCT05715216 | Recruiting | Phase 2 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | March 24, 2023 | April 30, 2025 |
| NCT05715229 | Recruiting | Phase 2 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | September 29, 2023 | April 28, 2026 |
| NCT04248569 | Recruiting | Phase 1 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | April 20, 2020 | March 1, 2027 |
| NCT05465174 | Recruiting | Phase 2 | Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | September 12, 2022 | March 1, 2028 |
| NCT05327686 | Recruiting | Phase 2 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study | June 30, 2022 | June 15, 2032 |
| NCT04848116 | Recruiting | Phase 2 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca | April 24, 2021 | April 2026 |
| NCT03921684 | Recruiting | Phase 2 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | April 2019 | October 2025 |
| NCT03799445 | Recruiting | Phase 2 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | July 25, 2019 | June 30, 2025 |
| NCT05308446 | Recruiting | Phase 2 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | July 19, 2022 | August 31, 2024 |
| NCT05721846 | Recruiting | Phase 1 | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer | May 3, 2023 | December 2025 |
| NCT05723055 | Recruiting | Phase 2 | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | April 18, 2023 | April 2028 |
| NCT05215470 | Recruiting | Phase 2 | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | January 18, 2022 | November 30, 2026 |
| NCT05322577 | Recruiting | Phase 1 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. | May 17, 2022 | April 1, 2028 |
| NCT05732389 | Recruiting | Phase 2 | Immunotherapy in Patients With Early dMMR Rectal Cancer | February 1, 2023 | February 2027 |
| NCT04848519 | Recruiting | Phase 2 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | May 20, 2021 | January 1, 2027 |
| NCT03690986 | Recruiting | Phase 1 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | November 1, 2018 | July 26, 2025 |
| NCT05327270 | Recruiting | Phase 1 | Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | September 13, 2022 | June 30, 2024 |
| NCT06049576 | Recruiting | Phase 1 | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | October 6, 2023 | March 14, 2026 |
| NCT05767684 | Recruiting | Phase 1 | Neoantigen Derived DCs as Cancer Treatment | June 1, 2023 | March 30, 2026 |
| NCT05393674 | Recruiting | Phase 2 | Fedratinib in Combination With Nivolumab | June 14, 2022 | June 30, 2026 |
| NCT06191796 | Recruiting | Phase 1/Phase 2 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | January 25, 2024 | January 2027 |
| NCT04322955 | Recruiting | Phase 2 | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | June 22, 2020 | February 2027 |
| NCT04323046 | Recruiting | Phase 1 | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | October 2, 2020 | March 1, 2029 |
| NCT05779423 | Recruiting | Phase 2 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | September 23, 2023 | January 1, 2028 |
| NCT04336241 | Recruiting | Phase 1 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | October 17, 2019 | April 30, 2028 |
| NCT05795244 | Recruiting | Phase 2 | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | October 31, 2023 | December 2029 |
| NCT05476796 | Recruiting | Phase 2 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | June 23, 2023 | January 2027 |
| NCT05802056 | Recruiting | Phase 1 | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | November 29, 2023 | January 2026 |
| NCT03685890 | Recruiting | Phase 1/Phase 2 | Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | April 1, 2019 | December 31, 2029 |
| NCT02955290 | Recruiting | Phase 1/Phase 2 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | December 22, 2016 | December 9, 2027 |
| NCT06203600 | Recruiting | Phase 2/Phase 3 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | January 31, 2025 | October 31, 2027 |
| NCT05817903 | Recruiting | Phase 2 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | April 18, 2023 | April 1, 2027 |
| NCT05821751 | Recruiting | N/A | The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors | December 2, 2021 | December 2, 2025 |
| NCT04375527 | Recruiting | Phase 2 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | December 3, 2020 | June 1, 2025 |
| NCT04876313 | Recruiting | Phase 2 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) | January 27, 2022 | June 2025 |
| NCT03682276 | Recruiting | Phase 1/Phase 2 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | March 1, 2019 | December 1, 2023 |
| NCT04387084 | Recruiting | Phase 1 | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | August 12, 2020 | August 12, 2025 |
| NCT03681561 | Recruiting | Phase 1/Phase 2 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | September 13, 2018 | December 2026 |
| NCT05834348 | Recruiting | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | June 26, 2023 | February 3, 2025 | |
| NCT05859477 | Recruiting | Phase 2 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer | June 5, 2022 | December 1, 2024 |
| NCT03944915 | Recruiting | Phase 2 | De-Escalation Therapy for Human Papillomavirus Negative Disease | August 26, 2019 | July 1, 2024 |
| NCT04413123 | Recruiting | Phase 2 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | November 5, 2020 | December 20, 2025 |
| NCT04884282 | Recruiting | Phase 2 | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) | October 12, 2021 | May 17, 2025 |
| NCT04416568 | Recruiting | Phase 2 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | August 14, 2020 | October 2025 |
| NCT05867121 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | October 2, 2023 | December 30, 2025 |
| NCT04423029 | Recruiting | Phase 1/Phase 2 | A Study of DF6002 Alone and in Combination With Nivolumab | July 13, 2020 | December 16, 2025 |
| NCT03104439 | Recruiting | Phase 2 | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | May 10, 2017 | October 2026 |
| NCT06237920 | Recruiting | Phase 2 | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | February 19, 2024 | August 1, 2028 |
| NCT06112314 | Recruiting | Phase 3 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | December 18, 2023 | December 1, 2027 |
| NCT03866382 | Recruiting | Phase 2 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | May 13, 2019 | February 28, 2025 |
| NCT04444921 | Recruiting | Phase 3 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | November 17, 2020 | March 31, 2026 |
| NCT05888831 | Recruiting | Phase 1/Phase 2 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | June 6, 2023 | July 1, 2027 |
| NCT05289193 | Recruiting | Phase 2 | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | March 11, 2022 | March 11, 2025 |
| NCT05203913 | Recruiting | Phase 2 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer | May 1, 2023 | June 15, 2026 |
| NCT04462406 | Recruiting | Phase 2 | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | February 9, 2021 | August 29, 2026 |
| NCT03816345 | Recruiting | Phase 1 | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | July 16, 2019 | August 31, 2024 |
| NCT05199285 | Recruiting | Phase 2 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | January 19, 2023 | January 31, 2027 |
| NCT04688658 | Recruiting | Phase 1/Phase 2 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | July 21, 2021 | October 2029 |
| NCT05896839 | Recruiting | Phase 1/Phase 2 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | August 11, 2024 | January 31, 2027 |
| NCT03258567 | Recruiting | Phase 2 | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | April 26, 2018 | June 1, 2031 |
| NCT05188118 | Recruiting | Early Phase 1 | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | February 24, 2023 | December 2025 |
| NCT01703949 | Recruiting | Phase 2 | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | March 20, 2013 | September 1, 2025 |
| NCT05187182 | Recruiting | Phase 1 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | June 2, 2023 | June 30, 2027 |
| NCT03646617 | Recruiting | Phase 2 | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | November 27, 2018 | December 31, 2025 |
| NCT05180799 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | August 3, 2022 | June 30, 2025 |
| NCT03645928 | Recruiting | Phase 2 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | May 7, 2019 | August 9, 2029 |
| NCT05176483 | Recruiting | Phase 1 | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors | December 14, 2021 | May 2026 |
| NCT04464759 | Recruiting | Phase 1/Phase 2 | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | October 21, 2020 | October 30, 2025 |
| NCT06319196 | Recruiting | Phase 2 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | May 1, 2024 | February 15, 2030 |
| NCT04465643 | Recruiting | Phase 1 | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | June 8, 2021 | August 2026 |
| NCT05163041 | Recruiting | Phase 1/Phase 2 | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | November 2, 2021 | December 2025 |
| NCT05272384 | Recruiting | Phase 1 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | November 3, 2022 | June 28, 2027 |
| NCT04472767 | Recruiting | Phase 2 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | August 7, 2020 | September 1, 2027 |
| NCT05162976 | Recruiting | Phase 1 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | January 3, 2022 | May 30, 2025 |
| NCT05898828 | Recruiting | Phase 1/Phase 2 | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | June 23, 2024 | December 30, 2036 |
| NCT02925234 | Recruiting | Phase 2 | The Drug Rediscovery Protocol (DRUP Trial) | August 2016 | December 2027 |
| NCT05904080 | Recruiting | Phase 2 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | February 19, 2024 | June 16, 2028 |
| NCT03607890 | Recruiting | Phase 2 | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | November 16, 2018 | October 2024 |
| NCT05480384 | Recruiting | Phase 2 | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction | July 14, 2023 | January 2027 |
| NCT04658147 | Recruiting | Phase 1 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | May 28, 2021 | June 1, 2026 |
| NCT05482451 | Recruiting | Early Phase 1 | Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer | March 1, 2021 | February 28, 2025 |
| NCT02914405 | Recruiting | Phase 1 | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma | May 24, 2018 | July 31, 2025 |
| NCT03604978 | Recruiting | Phase 1/Phase 2 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | June 17, 2019 | December 31, 2024 |
| NCT05144529 | Recruiting | Phase 2 | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC | March 22, 2022 | December 2025 |
| NCT04495257 | Recruiting | Phase 1 | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | September 14, 2020 | February 2025 |
| NCT05136677 | Recruiting | Phase 2 | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants | January 25, 2022 | October 8, 2026 |
| NCT03097939 | Recruiting | Phase 2 | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | March 31, 2017 | December 31, 2024 |
| NCT06097728 | Recruiting | Phase 3 | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | November 9, 2023 | March 13, 2028 |
| NCT03138161 | Recruiting | Phase 1/Phase 2 | SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma | April 13, 2017 | March 31, 2025 |
| NCT05136196 | Recruiting | Phase 2 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | December 6, 2022 | September 1, 2024 |
| NCT04902040 | Recruiting | Phase 1/Phase 2 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | April 14, 2021 | June 1, 2025 |
| NCT03589339 | Recruiting | Phase 1 | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | January 16, 2019 | May 30, 2028 |
| NCT02194738 | Recruiting | N/A | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | September 26, 2014 | September 28, 2026 |
| NCT04495296 | Recruiting | Phase 1/Phase 2 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | August 13, 2020 | November 1, 2024 |
| NCT04902443 | Recruiting | Phase 1 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | December 10, 2021 | December 1, 2026 |
| NCT06295159 | Recruiting | Early Phase 1 | Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | February 28, 2024 | March 2027 |
| NCT04511013 | Recruiting | Phase 2 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | January 6, 2021 | June 30, 2027 |
| NCT05491616 | Recruiting | Phase 2 | Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study | September 29, 2022 | October 2026 |
| NCT04652960 | Recruiting | Phase 1 | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | October 21, 2021 | May 3, 2025 |
| NCT05112601 | Recruiting | Phase 2 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | June 2, 2022 | April 30, 2026 |
| NCT03080974 | Recruiting | Phase 2 | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | August 14, 2017 | April 1, 2026 |
| NCT05501665 | Suspended | Phase 1/Phase 2 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | May 9, 2023 | February 1, 2027 |
| NCT04091750 | Suspended | Phase 2 | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | March 2, 2020 | May 2024 |
| NCT04145115 | Suspended | Phase 2 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | December 24, 2020 | May 31, 2025 |
| NCT03604991 | Suspended | Phase 2/Phase 3 | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | May 3, 2019 | January 31, 2026 |
| NCT01896999 | Suspended | Phase 1/Phase 2 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | March 7, 2014 | March 20, 2025 |
| NCT04042116 | Suspended | Phase 1/Phase 2 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | July 29, 2019 | January 2024 |
| NCT03958383 | Suspended | Phase 1/Phase 2 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | January 30, 2020 | August 15, 2025 |
| NCT05836571 | Suspended | Phase 2 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | October 25, 2023 | May 15, 2026 |
| NCT04546399 | Suspended | Phase 2 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | December 4, 2020 | June 30, 2028 |
| NCT03432741 | Suspended | Phase 1 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | March 27, 2018 | May 1, 2026 |
| NCT05479045 | Suspended | Phase 2 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | June 2024 | November 2026 |
| NCT03952585 | Suspended | Phase 2/Phase 3 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | October 9, 2019 | February 28, 2025 |
| NCT03425331 | Suspended | Phase 2 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | February 28, 2018 | August 28, 2025 |
| NCT03970382 | Suspended | Phase 1 | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | July 3, 2019 | August 12, 2022 |
| NCT04751370 | Suspended | Phase 2 | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | February 8, 2022 | December 31, 2026 |
| NCT03704714 | Suspended | Phase 1/Phase 2 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | November 20, 2018 | June 11, 2025 |
| NCT04380545 | Suspended | Phase 1/Phase 2 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | January 13, 2021 | July 31, 2025 |
| NCT05498792 | Suspended | Early Phase 1 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | November 30, 2022 | September 2, 2025 |
| NCT04185311 | Terminated | Phase 1 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | July 10, 2019 | May 17, 2023 |
| NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT03106610 | Terminated | Phase 1 | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | July 7, 2017 | May 16, 2018 |
| NCT03903640 | Terminated | Phase 2 | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | October 14, 2019 | November 3, 2021 |
| NCT05435053 | Terminated | Phase 2 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer | September 8, 2022 | August 30, 2023 |
| NCT03906526 | Terminated | Phase 1 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | July 3, 2019 | January 24, 2022 |
| NCT03110107 | Terminated | Phase 1/Phase 2 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | May 4, 2017 | April 4, 2024 |
| NCT03782064 | Terminated | Phase 2 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | February 22, 2019 | January 31, 2021 |
| NCT03952325 | Terminated | Phase 2 | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | July 9, 2019 | June 23, 2021 |
| NCT03781960 | Terminated | Phase 2 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | July 31, 2019 | April 29, 2022 |
| NCT05581719 | Terminated | Phase 1/Phase 2 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | November 15, 2022 | April 15, 2024 |
| NCT03115801 | Terminated | Phase 2 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | November 2016 | October 13, 2020 |
| NCT04044430 | Terminated | Phase 1 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | August 31, 2020 | July 31, 2022 |
| NCT04057365 | Terminated | Phase 2 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | October 7, 2019 | September 25, 2022 |
| NCT03119428 | Terminated | Phase 1 | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | May 2, 2017 | May 15, 2019 |
| NCT04069936 | Terminated | Phase 2 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | October 15, 2019 | November 30, 2021 |
| NCT04088500 | Terminated | Phase 2 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | September 3, 2020 | November 15, 2021 |
| NCT03729245 | Terminated | Phase 3 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | December 18, 2018 | October 19, 2022 |
| NCT04119336 | Terminated | Phase 2 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | February 14, 2020 | March 30, 2022 |
| NCT03728465 | Terminated | Phase 2 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | April 10, 2018 | January 1, 2021 |
| NCT03724968 | Terminated | Phase 2 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | January 17, 2019 | May 28, 2020 |
| NCT04149574 | Terminated | Phase 3 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) | January 15, 2020 | October 31, 2023 |
| NCT03812562 | Terminated | Early Phase 1 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | February 7, 2019 | October 19, 2023 |
| NCT03121534 | Terminated | Phase 2 | Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation | June 22, 2017 | February 11, 2022 |
| NCT03707457 | Terminated | Phase 1 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | March 22, 2019 | June 18, 2020 |
| NCT04212026 | Terminated | Phase 2 | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. | June 28, 2020 | July 12, 2023 |
| NCT04258150 | Terminated | Phase 2 | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | April 16, 2020 | November 23, 2021 |
| NCT03695250 | Terminated | Phase 1/Phase 2 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | October 16, 2018 | March 12, 2021 |
| NCT03121677 | Terminated | Phase 1 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | October 16, 2018 | August 7, 2023 |
| NCT03693846 | Terminated | Phase 2 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | February 15, 2019 | March 6, 2021 |
| NCT04272333 | Terminated | Early Phase 1 | Intratumoral Microdosing of Motolimod in HNSCC | October 15, 2021 | March 25, 2022 |
| NCT04300140 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | February 26, 2021 | August 14, 2023 |
| NCT04311710 | Terminated | Phase 1 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types | June 25, 2020 | January 18, 2023 |
| NCT04319224 | Terminated | Phase 1/Phase 2 | Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors | March 10, 2020 | January 3, 2023 |
| NCT04340193 | Terminated | Phase 3 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer | September 15, 2020 | December 12, 2023 |
| NCT04410445 | Terminated | Phase 3 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | July 27, 2020 | September 22, 2022 |
| NCT04429321 | Terminated | Phase 1 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | August 26, 2020 | January 31, 2024 |
| NCT04434560 | Terminated | Phase 2 | Neoadjuvant Immunotherapy in Brain Metastases | November 4, 2020 | June 17, 2021 |
| NCT03663166 | Terminated | Phase 1/Phase 2 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | November 20, 2018 | October 22, 2021 |
| NCT04458909 | Terminated | Phase 3 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | December 9, 2020 | August 15, 2023 |
| NCT03662074 | Terminated | Phase 2 | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer | November 7, 2018 | February 3, 2022 |
| NCT03656627 | Terminated | Phase 1 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | June 27, 2019 | March 18, 2021 |
| NCT03655613 | Terminated | Phase 1/Phase 2 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | September 5, 2018 | December 15, 2021 |
| NCT03655444 | Terminated | Phase 1/Phase 2 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | May 29, 2019 | August 24, 2020 |
| NCT01940809 | Terminated | Phase 1 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | August 28, 2013 | March 4, 2022 |
| NCT03606174 | Terminated | Phase 2 | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma | September 11, 2018 | August 22, 2022 |
| NCT02054520 | Terminated | Phase 2 | Immunotherapy Study for Patients With Stage IV Melanoma | June 2014 | January 5, 2021 |
| NCT03597282 | Terminated | Phase 1 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | October 8, 2018 | August 11, 2020 |
| NCT02124850 | Terminated | Phase 1 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | October 28, 2014 | October 31, 2016 |
| NCT03597009 | Terminated | Phase 1/Phase 2 | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | March 6, 2019 | February 12, 2020 |
| NCT05116917 | Terminated | Phase 2 | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. | November 5, 2021 | October 19, 2023 |
| NCT02253992 | Terminated | Phase 1/Phase 2 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | September 29, 2014 | May 24, 2019 |
| NCT03572478 | Terminated | Phase 1/Phase 2 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | August 14, 2018 | October 1, 2020 |
| NCT02323126 | Terminated | Phase 2 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | February 9, 2015 | February 5, 2021 |
| NCT03562507 | Terminated | Phase 2 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | April 11, 2019 | October 18, 2022 |
| NCT02341625 | Terminated | Phase 1/Phase 2 | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | June 19, 2015 | May 7, 2020 |
| NCT03558750 | Terminated | Phase 1 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | June 14, 2018 | April 16, 2019 |
| NCT02421354 | Terminated | Phase 2 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | May 14, 2015 | April 13, 2018 |
| NCT02423954 | Terminated | Phase 1/Phase 2 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | April 2015 | November 1, 2017 |
| NCT03519308 | Terminated | Early Phase 1 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | July 29, 2020 | April 18, 2022 |
| NCT03519256 | Terminated | Phase 2 | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder | August 2, 2018 | August 24, 2022 |
| NCT02472977 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | July 13, 2015 | January 27, 2017 |
| NCT03511222 | Terminated | Phase 1 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | September 11, 2018 | May 28, 2020 |
| NCT03509584 | Terminated | Phase 1 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | June 7, 2018 | July 2, 2019 |
| NCT03502746 | Terminated | Phase 2 | Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | June 26, 2018 | November 9, 2023 |
| NCT04594811 | Terminated | Phase 1 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | January 21, 2021 | May 26, 2023 |
| NCT03495713 | Terminated | Phase 2 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | November 2, 2018 | April 20, 2022 |
| NCT03461952 | Terminated | Phase 2 | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | March 11, 2019 | February 9, 2022 |
| NCT03444753 | Terminated | Phase 1 | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | April 5, 2018 | February 14, 2022 |
| NCT02595918 | Terminated | Phase 1 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | May 19, 2016 | August 1, 2020 |
| NCT03437200 | Terminated | Phase 2 | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer | January 17, 2019 | October 7, 2022 |
| NCT03435640 | Terminated | Phase 1/Phase 2 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | March 15, 2018 | May 9, 2022 |
| NCT02599649 | Terminated | Phase 2 | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | March 21, 2016 | January 30, 2019 |
| NCT03425461 | Terminated | Phase 1 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | June 14, 2018 | March 4, 2021 |
| NCT03422094 | Terminated | Phase 1 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | October 31, 2018 | December 31, 2020 |
| NCT03420521 | Terminated | Phase 2 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | March 9, 2018 | November 24, 2021 |
| NCT02621515 | Terminated | Phase 2 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases | August 2016 | May 30, 2018 |
| NCT03406715 | Terminated | Phase 2 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | March 15, 2018 | May 16, 2022 |
| NCT02635061 | Terminated | Phase 1 | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer | August 25, 2016 | January 22, 2024 |
| NCT02648633 | Terminated | Phase 1 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | May 24, 2016 | February 21, 2017 |
| NCT04610658 | Terminated | Phase 1 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | November 23, 2020 | March 24, 2023 |
| NCT02681302 | Terminated | Phase 1/Phase 2 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence | June 7, 2016 | May 10, 2024 |
| NCT02702492 | Terminated | Phase 1 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | June 2016 | June 1, 2021 |
| NCT02712905 | Terminated | Phase 1/Phase 2 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | May 5, 2016 | April 14, 2022 |
| NCT03382912 | Terminated | Phase 2 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer | March 22, 2018 | March 3, 2020 |
| NCT03382886 | Terminated | Phase 1 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma | April 11, 2018 | July 2, 2019 |
| NCT02720484 | Terminated | Phase 2 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | March 30, 2016 | November 2, 2018 |
| NCT02723006 | Terminated | Phase 1 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | June 22, 2016 | May 11, 2018 |
| NCT03381118 | Terminated | Phase 2 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | June 30, 2017 | September 30, 2018 |
| NCT03371381 | Terminated | Phase 1/Phase 2 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | January 2, 2018 | October 9, 2018 |
| NCT02750514 | Terminated | Phase 2 | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | May 9, 2016 | January 29, 2020 |
| NCT02768558 | Terminated | Phase 3 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | October 17, 2016 | January 23, 2019 |
| NCT02771626 | Terminated | Phase 1/Phase 2 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | August 1, 2016 | April 24, 2020 |
| NCT02781506 | Terminated | Phase 2 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma | June 20, 2016 | May 24, 2021 |
| NCT03363776 | Terminated | Phase 1/Phase 2 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | December 6, 2017 | November 22, 2019 |
| NCT02819804 | Terminated | Phase 1 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 17, 2017 | August 30, 2018 |
| NCT02828124 | Terminated | Phase 1/Phase 2 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | August 23, 2016 | January 8, 2018 |
| NCT03351231 | Terminated | Phase 1/Phase 2 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer | November 27, 2017 | August 28, 2018 |
| NCT03348904 | Terminated | Phase 3 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | December 27, 2017 | May 22, 2018 |
| NCT02831933 | Terminated | Phase 2 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma | February 15, 2017 | November 5, 2020 |
| NCT03347123 | Terminated | Phase 1/Phase 2 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | March 21, 2018 | January 29, 2021 |
| NCT02834247 | Terminated | Phase 1 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | August 12, 2016 | November 30, 2018 |
| NCT03342417 | Terminated | Phase 2 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | February 14, 2018 | May 29, 2019 |
| NCT02846376 | Terminated | Phase 1 | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant | March 8, 2019 | December 21, 2023 |
| NCT02846792 | Terminated | Phase 1/Phase 2 | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | June 14, 2017 | August 16, 2018 |
| NCT03333746 | Terminated | Phase 2 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | March 21, 2018 | November 16, 2018 |
| NCT02862535 | Terminated | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | September 20, 2016 | October 25, 2019 |
| NCT02864316 | Terminated | Phase 2 | Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure | December 2016 | September 2018 |
| NCT03311334 | Terminated | Phase 1/Phase 2 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | December 14, 2017 | November 29, 2022 |
| NCT03302247 | Terminated | Phase 2 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | January 15, 2018 | July 12, 2019 |
| NCT02892734 | Terminated | Phase 2 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | September 18, 2017 | February 4, 2019 |
| NCT03301636 | Terminated | Phase 2 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | December 8, 2017 | November 4, 2019 |
| NCT04899921 | Terminated | Phase 2 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | June 30, 2021 | May 29, 2023 |
| NCT04655157 | Terminated | Phase 1/Phase 2 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma | May 28, 2021 | September 20, 2022 |
| NCT04892043 | Terminated | Phase 1 | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | August 19, 2021 | November 2, 2023 |
| NCT02923531 | Terminated | Phase 1/Phase 2 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | December 7, 2016 | August 8, 2018 |
| NCT04659369 | Terminated | Phase 1 | Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC | September 24, 2020 | October 16, 2023 |
| NCT03259516 | Terminated | Phase 1/Phase 2 | Nivolumab With Chemotherapy in Refractory MDS | May 25, 2017 | December 25, 2018 |
| NCT03259425 | Terminated | Phase 2 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | January 3, 2018 | September 25, 2020 |
| NCT03251924 | Terminated | Phase 1/Phase 2 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | September 1, 2017 | December 20, 2021 |
| NCT02949843 | Terminated | Phase 2 | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | March 10, 2017 | January 12, 2021 |
| NCT02954991 | Terminated | Phase 2 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | November 7, 2016 | November 4, 2021 |
| NCT02959554 | Terminated | Phase 2 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control | December 2016 | January 2021 |
| NCT02967133 | Terminated | Phase 2 | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | December 2016 | January 2018 |
| NCT03203304 | Terminated | Phase 1 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | August 25, 2017 | March 13, 2019 |
| NCT02978443 | Terminated | Phase 2 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | July 26, 2017 | August 2, 2022 |
| NCT02985554 | Terminated | Phase 1 | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies | March 20, 2017 | June 22, 2020 |
| NCT02992964 | Terminated | Phase 1/Phase 2 | Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers | May 15, 2017 | November 20, 2023 |
| NCT03168464 | Terminated | Phase 1/Phase 2 | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | October 9, 2017 | March 11, 2022 |
| NCT04730349 | Terminated | Phase 1/Phase 2 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | June 3, 2021 | June 22, 2022 |
| NCT03023527 | Terminated | Phase 1 | Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | January 2017 | January 2018 |
| NCT03026166 | Terminated | Phase 1/Phase 2 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | March 30, 2017 | July 3, 2019 |
| NCT03041181 | Terminated | Phase 2 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | January 27, 2017 | May 23, 2019 |
| NCT03050060 | Terminated | Phase 2 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | June 9, 2017 | July 12, 2020 |
| NCT03059147 | Terminated | Phase 1 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | March 27, 2017 | June 29, 2020 |
| NCT03138499 | Terminated | Phase 3 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, | June 26, 2017 | February 22, 2021 |
| NCT03071094 | Terminated | Phase 1/Phase 2 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | July 27, 2017 | February 3, 2021 |
| NCT03075553 | Terminated | Phase 2 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | May 17, 2017 | May 29, 2019 |
| NCT03091491 | Terminated | Phase 2 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | April 7, 2017 | November 18, 2019 |
| NCT04801966 | Terminated | N/A | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | September 23, 2021 | December 30, 2022 |
| NCT03100006 | Terminated | Phase 1/Phase 2 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | February 22, 2017 | April 17, 2020 |
| NCT03824704 | Terminated | Phase 2 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | August 23, 2019 | August 24, 2020 |
| NCT03652142 | Unknown status | Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma | May 1, 2018 | May 1, 2020 | |
| NCT04611165 | Unknown status | Phase 2 | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC | November 15, 2019 | December 30, 2022 |
| NCT03161756 | Unknown status | Phase 1/Phase 2 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | December 7, 2017 | December 2023 |
| NCT04771715 | Unknown status | Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer | May 1, 2019 | March 31, 2021 | |
| NCT02637531 | Unknown status | Phase 1 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | December 2015 | December 2022 |
| NCT04782791 | Unknown status | Phase 2 | Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer | May 1, 2022 | May 31, 2024 |
| NCT02626065 | Unknown status | Phase 4 | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies | April 23, 2015 | April 2018 |
| NCT02046733 | Unknown status | Phase 2 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | July 28, 2014 | June 2022 |
| NCT04267146 | Unknown status | Phase 1/Phase 2 | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma | July 15, 2019 | January 2024 |
| NCT04603248 | Unknown status | N/A | A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | August 30, 2020 | February 2023 |
| NCT04233840 | Unknown status | Phase 1/Phase 2 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | February 12, 2019 | July 31, 2023 |
| NCT04620954 | Unknown status | Phase 1/Phase 2 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | October 7, 2020 | July 2022 |
| NCT04023617 | Unknown status | Phase 2 | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC | July 8, 2019 | May 30, 2021 |
| NCT03993249 | Unknown status | Phase 2 | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy | May 28, 2019 | December 2023 |
| NCT04211896 | Unknown status | Phase 2 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | January 1, 2020 | January 1, 2022 |
| NCT02982486 | Unknown status | Phase 2 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | December 2017 | December 2020 |
| NCT05027204 | Unknown status | Phase 1/Phase 2 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | March 4, 2022 | December 31, 2023 |
| NCT03177239 | Unknown status | Phase 2 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | October 19, 2017 | December 31, 2022 |
| NCT04413838 | Unknown status | Phase 2 | Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection | June 15, 2020 | September 15, 2021 |
| NCT04377048 | Unknown status | Phase 2 | Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | July 1, 2020 | December 31, 2022 |
| NCT05236608 | Unknown status | Phase 1/Phase 2 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | November 12, 2021 | May 2024 |
| NCT04761744 | Unknown status | Phase 2 | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | June 14, 2019 | December 2021 |
| NCT05224999 | Unknown status | Phase 2 | Nivolumab for Recurrent/Metastatic Carcinosarcoma | November 13, 2019 | December 2023 |
| NCT02948348 | Unknown status | Phase 1/Phase 2 | Study to Nivolumab Following Preoperative Chemoradiotherapy | October 2016 | August 2022 |
| NCT02446860 | Unknown status | Phase 2 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) | April 2015 | May 2018 |
| NCT03987815 | Unknown status | Phase 2 | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma | August 1, 2019 | July 31, 2022 |
| NCT03048500 | Unknown status | Phase 2 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | July 12, 2017 | September 2021 |
| NCT03296137 | Unknown status | Phase 1/Phase 2 | Adoptive Cell Therapy Across Cancer Diagnoses | October 13, 2017 | September 30, 2020 |
| NCT04072198 | Unknown status | Phase 2 | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | September 26, 2019 | September 2022 |
| NCT04061863 | Unknown status | Phase 1/Phase 2 | Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer | August 1, 2019 | December 2022 |
| NCT03523572 | Unknown status | Phase 1 | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | June 20, 2018 | July 2022 |
| NCT02852083 | Unknown status | Phase 2 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC | January 2016 | July 2020 |
| NCT03529890 | Unknown status | Phase 2 | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder | February 4, 2019 | August 2023 |
| NCT03834233 | Unknown status | Phase 2 | Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | September 5, 2019 | December 1, 2022 |
| NCT02913417 | Unknown status | Phase 1/Phase 2 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | October 10, 2016 | June 2023 |
| NCT04356508 | Unknown status | Phase 2 | COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 | April 14, 2020 | August 31, 2021 |
| NCT03040791 | Unknown status | Phase 2 | Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) | June 1, 2018 | March 1, 2022 |
| NCT03557359 | Unknown status | Phase 2 | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | June 12, 2018 | December 2022 |
| NCT03784040 | Unknown status | Phase 1 | Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. | February 21, 2019 | March 1, 2024 |
| NCT04611126 | Unknown status | Phase 1/Phase 2 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | April 22, 2021 | December 2023 |
| NCT05213312 | Unknown status | Phase 2/Phase 3 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | June 1, 2022 | March 1, 2024 |
| NCT03569696 | Unknown status | Phase 2 | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy | October 8, 2018 | September 2023 |
| NCT03843515 | Unknown status | Phase 1 | Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction | April 11, 2019 | August 31, 2022 |
| NCT05130684 | Unknown status | Phase 2 | Neo-NTP-CRT for Locally Advanced ESCC | February 22, 2021 | March 1, 2024 |
| NCT03219671 | Unknown status | Phase 2 | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | April 1, 2018 | September 1, 2022 |
| NCT03371992 | Unknown status | Early Phase 1 | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC | March 9, 2018 | June 2021 |
| NCT04134182 | Unknown status | Phase 2 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | October 16, 2019 | December 2021 |
| NCT06400264 | Withdrawn | Phase 2 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | February 22, 2022 | January 17, 2023 |
| NCT02466568 | Withdrawn | Phase 1/Phase 2 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | July 2018 | July 2020 |
| NCT03126461 | Withdrawn | Phase 2 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | March 1, 2018 | December 31, 2022 |
| NCT03149120 | Withdrawn | Phase 2 | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | August 2017 | June 2022 |
| NCT03758729 | Withdrawn | Phase 2 | Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. | May 2020 | May 11, 2020 |
| NCT03342352 | Withdrawn | Phase 3 | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | December 15, 2017 | April 20, 2018 |
| NCT02400385 | Withdrawn | Phase 2 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | October 2014 | December 2015 |
| NCT04758949 | Withdrawn | Phase 2 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | August 25, 2021 | December 22, 2021 |
| NCT03326258 | Withdrawn | Phase 1/Phase 2 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | April 20, 2018 | April 20, 2018 |
| NCT03770299 | Withdrawn | Phase 2 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | January 15, 2021 | March 14, 2024 |
| NCT02357732 | Withdrawn | Phase 1 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | August 2015 | August 2015 |
| NCT04060407 | Withdrawn | Phase 1/Phase 2 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | June 15, 2021 | December 30, 2023 |
| NCT03575234 | Withdrawn | Phase 1 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | July 1, 2020 | January 31, 2026 |
| NCT03576963 | Withdrawn | Phase 1/Phase 2 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | January 30, 2020 | January 30, 2023 |
| NCT03767439 | Withdrawn | Phase 2 | Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | July 2019 | February 2020 |
| NCT04044651 | Withdrawn | Phase 2/Phase 3 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | October 30, 2019 | September 30, 2022 |
| NCT04500548 | Withdrawn | Phase 1 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | January 28, 2021 | June 21, 2022 |
| NCT04044209 | Withdrawn | Phase 2 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS | February 12, 2020 | September 2023 |
| NCT03048136 | Withdrawn | Phase 3 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer | March 9, 2018 | September 29, 2019 |
| NCT03283046 | Withdrawn | Phase 1 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | October 2017 | October 2020 |
| NCT03927248 | Withdrawn | Phase 1/Phase 2 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | September 2020 | December 2021 |
| NCT04495010 | Withdrawn | Phase 2 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | March 31, 2021 | October 23, 2027 |
| NCT02924233 | Withdrawn | Phase 1/Phase 2 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | November 2016 | February 2017 |
| NCT05153304 | Withdrawn | Phase 1/Phase 2 | Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | June 2024 | June 2027 |
| NCT04891718 | Withdrawn | Early Phase 1 | CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | September 15, 2021 | June 5, 2022 |
| NCT04007588 | Withdrawn | Phase 2 | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | September 6, 2019 | December 19, 2019 |
| NCT03652233 | Withdrawn | Phase 1 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | November 2, 2018 | November 2022 |
| NCT04430985 | Withdrawn | Phase 2 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer | September 30, 2020 | September 6, 2021 |
| NCT04361058 | Withdrawn | Phase 1 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | April 13, 2020 | April 20, 2021 |
| NCT03920631 | Withdrawn | Phase 1 | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas | July 10, 2020 | May 15, 2023 |
| NCT02950038 | Withdrawn | Phase 2 | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | December 2016 | |
| NCT03227432 | Withdrawn | Phase 2 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | December 2018 | December 31, 2024 |
| NCT03768531 | Withdrawn | Phase 2 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | June 14, 2019 | January 2023 |
| NCT03220009 | Withdrawn | Phase 2 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | November 3, 2017 | July 1, 2021 |
| NCT02962804 | Withdrawn | Phase 2 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | ||
| NCT04315155 | Withdrawn | Phase 1 | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation | October 2020 | September 2025 |
| NCT05743270 | Withdrawn | Phase 2 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | January 30, 2024 | June 1, 2026 |
| NCT05496192 | Withdrawn | Phase 2 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | May 31, 2023 | June 24, 2026 |
| NCT03704077 | Withdrawn | Phase 2 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | October 31, 2019 | September 30, 2024 |
| NCT03879811 | Withdrawn | Phase 2 | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer | March 13, 2019 | March 2021 |
| NCT03121417 | Withdrawn | Phase 2 | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | July 21, 2017 | March 9, 2019 |
| NCT04151563 | Withdrawn | Phase 1/Phase 2 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | April 15, 2021 | May 13, 2026 |
| NCT03386838 | Withdrawn | Phase 3 | An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck | March 28, 2018 | April 19, 2018 |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT04149275 | Withdrawn | Phase 2 | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma | February 2021 | February 2021 |
| NCT03390738 | Withdrawn | Phase 2 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | June 2018 | June 2019 |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT03982121 | Withdrawn | Phase 1 | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy | June 4, 2019 | February 12, 2020 |
| NCT03167177 | Withdrawn | Phase 1/Phase 2 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT04955262 | Withdrawn | Phase 1 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | August 2019 | January 2022 |
| NCT06247540 | Withdrawn | Phase 2 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | March 29, 2024 | December 29, 2031 |
| NCT02639234 | Withdrawn | Phase 2 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | March 2016 | March 2017 |
| NCT03417037 | Withdrawn | Phase 3 | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer | May 24, 2018 | August 20, 2025 |
| NCT03014804 | Withdrawn | Phase 2 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | December 1, 2019 | December 1, 2022 |
| NCT04128020 | Withdrawn | Phase 1 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | October 10, 2019 | September 28, 2020 |
| NCT04125719 | Withdrawn | Phase 1 | PVSRIPO in Combination With Nivolumab in Melanoma | June 1, 2020 | October 1, 2024 |
| NCT03726281 | Withdrawn | Phase 2 | Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors | October 1, 2018 | June 30, 2019 |
| NCT04965714 | Withdrawn | Phase 2 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | April 13, 2022 | February 10, 2023 |
| NCT05022394 | Withdrawn | Phase 1/Phase 2 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | February 18, 2021 | February 18, 2021 |
| NCT03149159 | Withdrawn | Phase 2 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | April 1, 2018 | April 1, 2018 |
| NCT05039736 | Withdrawn | Phase 2 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | February 24, 2023 | May 3, 2023 |
| NCT03808168 | Withdrawn | Phase 2 | Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia | January 15, 2019 | June 1, 2020 |
| NCT03023904 | Withdrawn | Phase 2 | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | December 29, 2017 | July 30, 2020 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Opdivo
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2014
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2014
- Target (Drug list of Screening Committee of Anticancer Drugs)
- PD-1
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- メラノーマ
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 非小細胞肺がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 腎がん